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Zusammenfassung  
Unter normalen Umständen wird Zell Homöostase sowie Zellzahl und folglich die 
Gewährleistung der Gewebsarchitektur - und Funktion in gesundem Gewebe durch 
exakte Regulierung, Produktion und Freilassung von Wachstums fördernden 
Signalen gewährleistet, die den Eintritt in den Zellwachstums und Zellteilungs Zyklus 
dirigieren. Deregulierung dieser Signale, die hauptsächlich durch Wachstumsfaktoren 
gesteuert werden, führt oft zu erhöhter Proliferation und Wachstum und folglich 
Tumor Entstehung. Erhöhte Menge des Epidermalen Wachstums Faktor Rezeptor 
(EGFR) wurden in vielen Krebsarten, inklusive Ovar Karzinomen, nachgewiesen was 
meist mit einer schlechteren Prognose für Patienten verbunden war. In meiner Arbeit 
versuchte ich herauszufinden welchen Einfluss die Deregulierung der EGFR 
Degradierung durch den ESCRT (Endosomal Sorting Complex required for 
Transport) auf Tumorformation hat. HCRP1, ein Mitglied des ESCRT I, ist essentiell 
für korrekte Rezeptor Degradation von ubiquitinierten Membranrezeptoren und 
folglich korrekte Zellfunktion. Die in dieser Arbeit präsentierten Ergebnisse 
charakterisieren HCRP1 als neuartiges „Tumor Supressor Gen“ mit einer essentiellen 
Rolle bei der Degradation von Rezeptor Tyrosin Kinasen und als potentieller 
Biomarker bei Ovar Karzinomen. 
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Abstract 
Under normal conditions, homeostasis of cell number and hence the maintenance of 
tissue architecture and function in healthy tissue is ensured by the tight regulation, 
production and release of growth- promoting signals that direct the entry into the cell 
growth- and division cycle. Deregulation of these signals, which are mostly mediated 
by growth factors, often leads to enhanced proliferation and growth and consequently 
tumor formation. Elevated levels of the epidermal growth factor receptor (EGFR) 
were found in many kinds of cancer including ovarian cancer and are associated with 
a negative outcome for patients. In my work, I aimed at understanding the impact of 
deregulated EGFR degradation via ESCRT (Endosomal sorting complex required for 
transport) on tumor formation, focusing on HCRP1, a member of ESCRT I, which is 
crucial for proper receptor degradation of ubiquitinated membrane receptors. The 
results presented in this thesis, characterize HCRP1 as a novel tumor suppressor 
gene with an essential role in the degradation of receptor tyrosine kinases and as a 
potential biomarker in ovarian cancer and beyond. 
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1. Introduction  
 
Cancer is a complex, multistep disease which is classically regarded to arise due to 
six distinct molecular pathways which are required for the development of human 
tumors (as reviewed in Hallmarks of cancer: The next generation (Hanahan and 
Weinberg)). These six “hallmarks of cancer” are believed to constitute the origin of 
human cancer: Sustaining proliferative signals, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis and activating 
invasion and metastasis. 
The formation of cancer cells involves their ability to sustain chronic proliferation. 
Normally, homeostasis of cell number and hence maintenance of normal tissue 
architecture and function is ensured by tight regulation production and release of 
growth- promoting signals that direct the entry into the cell growth- and division cycle. 
Deregulation of these signals, which are mostly growth factors that bind cell surface 
receptors containing intracellular tyrosine kinase domains, leads to enhanced 
proliferation and growth and hence tumor formation (Hanahan and Weinberg).  
Cancer cells use various ways to amplify proliferative signaling: 1) the production of 
growth factor ligands, to which cells respond through expression of and signaling via 
cognate receptors 2) sending of signals to stimulate normal cells in the tumor-
associated stroma, which consequently respond by supplying cancer cells with 
growth factors 3) enhanced levels of receptor proteins at the cancer cell surface 
which leads to hyper-responsitivity to ligands or structural alterations of receptor 
molecules which alleviates ligand-independent firing. Yet another way to increase 
proliferation is the alteration of signaling pathways operating downstream of these 
receptors (Bhowmick et al., 2004; Cheng et al., 2008). 
Constitutive activation of proliferative signaling is usually established by activated 
growth factor receptors and is often linked to certain somatic mutations in the cancer 
cell genome. For an instance, it was shown that approximately 40% of human 
melanomas display an activating mutation which affects the structure of the B - Raf 
protein, resulting in constitutive signaling through the Raf to mitogen - activated 
protein (MAP) - kinase pathway (Davies and Samuels; Hanahan and Weinberg). 
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The EGFR/ErbB receptor proto–oncogene family, which comprises four structurally 
related transmembrane receptors, plays an important role in molecular pathogenesis 
of human cancer and is a promising target for personalized anti cancer treatment, as 
it was shown that elevated levels of ErbB signaling are associated with poor 
prognosis in cancer patients (Holbro et al., 2003; Hynes and Lane, 2005; Yarden, 
2001).  
In this thesis, I characterize HCRP1, a member of the Endosomal Sorting Complex 
Required for Transport I (ESCRT I), which is crucial for proper (EGFR) - receptor 
degradation and hence correct signaling, as a promising target and marker for anti 
cancer therapy.  
 
1.1. Growth factors- Introduction 
Growth factor receptors play a crucial role in cellular proliferation, survival, migration 
and differentiation. To control their cell surface expression and hence the 
transduction of signals delivered in response to growth factors, proper down-
regulation of mitogenic receptors is crucial. It was shown that overstimulation or 
hyperactivation through mutation of the EGFR was found to be associated with 
enhanced tumor development leading to a more aggressive disease and hence an 
unfavorable clinical outcome (Holbro et al., 2003; Hynes and Lane, 2005; Yarden, 
2001). Due to these facts, signaling pathways and their associated downstream 
signaling cascades represent promising targets for cancer therapy. To ensure proper 
EGFR signaling, internalization via endocytosis is crucial for receptor down-regulation 
(Maxfield and McGraw, 2004). This step can lead to recycling of the receptor back to 
the cell surface, entry into the trans-Golgi network or transport into intraluminal 
vesicles and the formation of mutivesicular bodies (MVBs), which are then degraded 
by fusion with the lysosome (Katzmann et al., 2002; Raiborg et al., 2003). The 
Endosomal sorting complex required for transport ESCRT comprises four members 
(ESCRT 0-III) (Hurley and Hanson) and is discussed in detail later.  
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1.2. The EGFR pathway  
 
Figure 1: The EGFR signaling pathways and its inhibitors. Activation of EGFR leads 
to homo/heterodimerization and cytosolic tyrosine residue phosphorylation. STAT 
transcription factors and Phosphlipase C can bind directly to the EGFR receptor, 
compared to the Ras/Raf/MAPK – and PI3K pathway which need adaptor molecules 
(yellow) for activation. PI3K can also bind directly to the ErbB unit of a heterodimer 
formed with EGFR. The activated receptor can be internalized via endocytosis and 
can be either lysosomaly degraded or translocated into the nucleus leading to the 
activation of genes involved in proliferation, survival, invasion and metastasis. EGFR 
inhibition can be established by two main mechanisms: mAb which compete for 
ligand binding and small molecule TKI which block ATP binding to the kinase domain 
of the receptor. DAG, 1, 2-diacylglycerol; IP3, inositol 1,3,5-triphosphate; PLCg, 
phospholipase Cg; Erk-1, extracellular signal-regulated kinase-1; Erk-2, extracellular 
signal-regulated kinase-2; FAK, focal adhesion kinase; PKC, protein kinase C. 
(figure taken from (Scaltriti and Baselga, 2006) ) 
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Signal transduction initiated by binding of extracellular ligands to transmembrane 
receptors and hence activation or repression of distinct target gene is essential for 
cellular response to environmental stimuli. The EGFR- family consists of four 
members: EGFR (ErbB1/Her-1), ErbB2/Neu/HER-2, ErbB3/HER-3 and ErbB4/HER-4 
(Schlessinger, 2002; Sibilia et al., 2007) and is a class of receptor tyrosine kinases 
(RTKs) (SIMON 2000). Upon ligand binding, EGFR is activated which leads to 
receptor dimerization and autophosphorylation of cytoplasmatic tyrosine residues. 
Subsequently, the phosphor tyrosine residues serve as a docking platform for several 
adaptor molecules which induce the activation of a number of pathways including the 
RAS-RAF-MEK-ERK pathway, the STAT3 and STAT5, the PLC-gamma PKC and the 
PI3K-Akt-mTOR pathway. MAPK and STAT signaling mostly mediate differentiation 
and proliferation, whereas Akt – signaling leads to the activation of pro-survival and 
anti- apoptotic pathways (Schlessinger, 2002; Simon, 2000; Yarden, 2001). Ligand 
binding can induce the formation of hetero - or homodimers, which is the basis for the 
complexity of tissue specific ErbB signaling. This complexity is further amplified by 
the diversity of ligands which can bind to the ErbB receptors: in humans alone, more 
than 30 ligands have been identified that bind to the EGFR family, including the EGF- 
like ligands, transforming growth factor α (TGFα) and heregulins (HRGs also known 
as neuregulins) (Siwak et al.). This cell-type specific expression of ErbB receptors 
and the presence of the various ligands in the cellular environment result in the 
specificity of ErbB signaling for the individual cell types (Sibilia et al., 2007).  
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Figure 2: Structure of the Epidermal Growth Factor Receptor (EGFR). The EGFR is 
subdivided into three domains 1) extracellular (consisting of 4 subdomains, two 
ligand binding and two receptor dimerization domains), 2) transmembrane and 3) 
intracellular domains. The cytoplasmatic tail containing the tyrosine kinase domain is 
highly conserved among the EGFR family members. Phosphorylated tyrosine 
residues serve as docking sites for proteins with phosphotyrosine binding domains 
and SRC homology 2 binding domains. 
(figure taken from (Siwak et al.)) 
 
The EGFR receptor comprises three domains 1) an extracellular domain (ECD) 2) a 
transmembrane domain (TMD) and 3) an intracellular domain (ICD). The ECD is 
highly glycosylated and can be divided into four subdomains (I – IV) of which I and III 
confer ligand binding specificity and the cysteine rich subdomains II and IV, which is 
characteristic for the type I receptor tyrosine kinases. The TMD which is built of 
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mainly hydrophobic amino acid residues is crucial for anchoring the receptor in the 
cell membrane, for signal transduction from the ECD to the ICD after ligand binding 
and for the stabilization of receptor dimerization. The ICD comprises three 
subdomains, a juxtamembrane (JD) domain, a tyrosine kinase domain (TKD) and a 
carboxy-terminal regulatory domain (RD). The JD reduces ligand affinity by reducing 
the tyrosine kinase activity and additionally increases receptor internalization after 
ligand binding, which leads to down regulated ErbB receptor signaling. The TKD is 
highly conserved between the ErbB/EGFR receptor tyrosine kinases and is needed 
for autophosphorylation upon ligand binding. The RD functions as a regulator of 
kinase activity and recruits exogenous substrates that have SH2 (Src homology 2) or 
PTB (protein tyrosine binding motifs) (Schlessinger, 2002).  
 
Figure 3 Representation of the signaling networks of the 4 EGFR family members 
EGFR, HER2, HER3 and HER4 (numbers 1-4). Multiple ligands are known to bind to 
the EGFR family including EGF-and EGF-like ligands, transforming growth factor 
(TGF)-α and heregulins (HRGs, also known as neuregulins, NRGs). Numbers 
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underneath the ligands indicate to which EGFR family member ligands preferably 
bind to. There is no known ligand binding to HER2, while it is the preferred binding 
partner for all EGFR family members. Signal transduction is established by 
intracellular adaptor proteins, activating cascades such as the Ras/Raf/MAPK and 
PI3K/Akt. Proteins downstream of these cascades can be translocated into the 
nucleus where they can activate transcription factors (TF) such as MYC, ELK and 
FOS/JUN. The activated TFs mainly control the expression of genes involved in 
cellular responses such as proliferation, differentiation, cell mobility, survival and 
tumorgenesis. PLCγ: Phospholipase Cγ; SHP2: SRC homology phosphatase 2; 
GAP: GTPase activating protein; SHC: SRC homology 2 domain and collagen-
containing protein; PKC: Protein kinase C; MEK: MAPK/ERK kinase; PAK: P21-
activated kinase; JNKK: JNK kinase; JNK: JUN N-terminal kinase; EGR1: Early 
growth response protein 1; STAT: Signal transducer and activator of transcription 
(figure taken from (Siwak et al.)) 
 
1.3. EGFR and hepatocellular carcinoma formation 
Human hepatocellular carcinoma HCC is one of the most lethal cancers being one of 
the most common cancer-related causes of death worldwide (Huether et al., 2005). 
HCCs are complex heterogenous neoplasms and are the second most lethal cancer, 
with an 8,9 % 5-year survival rate, following pancreatic ductual adenocarcinoma. 
Studies show (Breuhahn et al., 2006) that growth factor pathways, including the 
EGFR pathway are often deregulated in HCC, often combined with EGFR-ligand 
over-expression (Breuhahn et al., 2006). This leads to altered signaling of various 
pathways, such as the RAS-RAF-MEK-ERK, the PI3K-AKT and the PLC-gamma-
Pathway (Sibilia et al., 2007). 
In general EGFR plays an important role in liver function, as mature liver cells 
express high levels of EGFR when compared with other adult cells. EGFR - ligands 
like EGF, TGF- α, AR and HB-EGFR were shown to be potent mitogens for cultured 
hepatocytes and seem to display hepatoprotective and regenerative potential. 
Additionally they are required for liver regeneration, which was demonstrated by 
partial hepatectomy in the corresponding knock-out mice. In HCC, EGFR or other 
growth factors are often deregulated, EGRF being up-regulated in 68%, ERbB2 in 
21%, ErbB3 I 84% and ErbB4 in 61% of HCC (Sibilia et al., 2007). Especially over-
expression of ERbB1 and ErbB3 contribute to more aggressive tumors and poorly 
differentiated HCCs additionally ErbB1 is associated with Metastasis and poor 
survival rate. Both genetic and pharmacological studies emphasize the importance of 
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EGFR signaling in HCC development. Studies with transgenic mice display that 
treatment with hepatocarcinogenes led to the development of well differentiated 
multifocal HCCs in mice expressing TGF – α, an important EGFR ligand, from the 
metallothionein- 1 (MT) promoter, whereas in TGF – α deficient mice this treatment 
led only to formation of small tumors (Jhappan et al., 1990). Treatment of HCC cells 
with the anti - EGFR antibody Cetuximab resulted in inhibited proliferation (Huether et 
al., 2005) and induced apoptosis (Breuhahn et al., 2006). Similar results were shown 
by treating HCC cells with Gefitinib, an EGFR-tyrosine kinase inhibitor, leading to 
growth inhibition and cell cycle arrest (Breuhahn et al., 2006; Sibilia et al., 2007). 
 
1.4. EGFR in ovarian cancer  
Aberrant signaling of the EGFR - receptor tyrosine kinase family and their 
downstream targets is associated with various kinds of cancer including epithelial 
ovarian cancer (Lafky et al., 2008; Salomon et al., 1995). Epithelial ovarian cancer 
accounts for 90% of ovarian cancer and it was shown that EGFR is over expressed in 
about 60% of ovarian cancers (Dimova et al., 2006; Lin et al., 2009). Treatment of 
human ovarian cancer cell lines with EGF resulted in significantly increased 
expression of proteins involved in invasion (Henic et al., 2006) and altered signaling 
of pathways associated with angiogenesis. EGF treatment of the ovarian 
adenocarcinoma cell line OVCAR – 3 led to elevated levels of H2O2 which triggers 
the activation of the AKT –P70S6K pathway and increases vascular endothelial 
growth factor transcription through hypoxia – inducible factor 1α expression (Liu et 
al., 2006). 
1.5. The EGFR Degradation Pathway 
As mentioned above, the phosphotyrosine residues in the cytoplasmic domain of 
EGFR serve as a docking platform of several adaptor molecules, some of which are 
crucial for proper degradation of ligand activated EGFR (Kirisits et al., 2007; 
Sweeney and Carraway, 2004). Proteins from the Cbl family play a key role in 
regulating RTK signaling including EGFR, platelet derived growth factor receptor 
(PDGFR), colony stimulation factor (CSF-1) and Her2 (Thien and Langdon, 2001). 
Ubiquitination is one of the major steps in EGFR degradation and was considered to 
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be responsible for proteasomal delivery of its substrates. As EGFR is degraded in 
lysosomes an alternative mechanism of ubiquitination is required. Normally, proteins 
destined for degradation by the proteasome get polyubiquitinated, whereas EGFR is 
monoubiquitinated at multiple sites as a signal to enter the endosomal pathway. C-
Clb is an E3 ligase which is involved in EGFR degradation by being recruited to the 
plasma membrane upon ligand binding which in turn leads to tyrosine 
phosphorylation by EGFR and hence mediates ubiquitination and intracellular 
receptor handling (Kirisits et al., 2007). After attachment to the EGFR phosphorylated 
tyrosine residue 1045 (pTyr 1045), c-Clb attaches ubiquitin to the bound receptor. 
The actual internalization of the receptor is established by clathrin coated pits (CCPs) 
which requires guidance of the receptor to CCPs by the interaction of Epidermal 
Growth Factor pathway substrate 15 (Esp15) with the clathrin adaptor complex (AP-
2) and the ubiquitinated receptor or EGFR associated c-Clb (de Melker et al., 2004). 
Cbl-interacting protein of 85 kDa (CIN85) also guides EGFR - c-Clb complexes to 
CCPs by interacting with Endophilin, which is a CCP regulatory element. The growth 
factor receptor binding protein 2 (Grb2) is another player involved in the 
internalization of EGFR by facilitating the interaction between EGFR and c-Clb 
(Huang and Sorkin, 2005). Vesicle fission from the plasma membrane is mediated by 
Dynamin, a GTPase (McNiven et al., 2000). This is followed by clathrin shedding 
which leads to the fusion of the EGFR containing vesicle with cytoplasmatic vesicular 
structures which is carried out by Ras associated protein 5 (Rab5) another GTPase 
(Kirisits et al., 2007; Zerial and McBride, 2001). 
The Endosomal Sorting Complexes Required for transport (ESCRTs) comprises four 
members ESCR 0-III and is crucial for EGFR degradation and its sorting into 
lysosomes. ESCRT0 is responsible for clustering of ubiquitylated cargo, ESCRT I 
and ESCRT II are directly involved in membrane budding and ESCRTIII is 
responsible for membrane scission. 
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Figure 4 The EGFR degradation pathway. Upon ligand binding EGFR forms hetero- 
or homodimers followed by autophosphorylation. c – Cbl gets phosphorylated and is 
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recruited to the receptor where it induces EGFR monoubiquitination. This causes 
EGFR to accumulate in clathrin coated pits which are interalised. Clathrin is shed and 
the intenalised vesicle fuses with the early endosome. MVB formation is triggered by 
the ESCRT complexes (0-III), (described in detail in text). In the end MVB fuses with 
the lysosome and the inner vesicles containing EGFR are proteolytic degraded in the 
lysosomal interior. 
(figure taken from(Kirisits et al., 2007)) 
 
1.6. The ESCRT complexes 
EGFR is degraded by being sorted to the lysosome (Sorkin and von Zastrow, 2009). 
This endosomal sorting is established by bud formation of portions of the endosome’s 
limiting membrane into the lumen of the endosome (Hurley and Hanson). 
Intralumenal vesicles (ILV) are formed by scission of these membrane buds, late 
endosomes filled with ILV are called multi vesicular bodies (MVB) (Gruenberg and 
Stenmark, 2004; Piper and Katzmann, 2007; Russell et al., 2006). In the end of the 
trafficking process, the MVB fuses with the lysosome where the contents are 
degraded at the hydrolytic lysosomal interior (Kirisits et al., 2007). 
Initially, the factors involved in proper MVB formation have been identified in 
saccharomyces cerevisiae. In yeast, the so called vacuolar protein sorting (VPS) 
genes (also known as class E genes), regulate correct MVB biogenesis, as the 
vacuole is the equivalent to the mammalian lysosome (Hurley and Hanson; Raymond 
et al., 1992). Loss of function of the VPS genes in yeast was shown to lead to altered 
trafficking of transmembrane proteins, which then accumulate in the yeast-specific 
class E compartment, because MVB formation is abolished (Babst, 2005). As 
analogous observations were made regarding the mammalian VPS homologues, it is 
assumable that their function in protein sorting is an evolutionarily conserved feature 
in eukaryotes (Babst, 2005). A list of yeast and mammalian homologues of the four 
ESCRT complex components and related VPS genes is given in table 1. The VPS 
genes mainly compose the core subunits of the four ESCRT complexes, or like the 
AAA + ATPase Vps4 provide the only energy input and the multifunctional ESCRT- 
associated Protein Bro1 domain- containing protein (Bro1) which displays regulatory 
functions by modulating ESCRT assembly. 
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Figure 5: Bud formation is established by ESCRT I and ESCRT II, which are located 
at the neck of the bud, in order to stabilize bud formation. On the right side bud 
formation in vivo is shown by a series of images of fixed and negatively stained cells, 
which are arranged into a time series. 
(figure taken from (Hurley and Hanson)) 
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Table 1: The Endosomal sorting complex required for transport ESCRT – members 
and function Abbreviations: AMSH, associated molecule with the SH3 domain of 
STAM; Bro1, Bro1 domain? containing protein 1; CHMP, charged multivesicular body 
protein; DID, DOA4?independent degradation protein; DUB, deubiquitylating enzyme; 
DUIM, double ?sided ubiquitin ?interacting motif; ESCRT, endosomal sorting complex 
required for transport; GAT, GGA and TOM; GLUE, GRAM?like ubiquitin?binding in 
EAP45; HRS, hepatocyte growth factor? regulated Tyr kinase substrate; Ist1, 
increased sodium tolerance protein 1; MIM, MIT? interacting motif; MIT, microtubule? 
interacting and transport; MVB, multivesicular body; NZF, Npl4?type zinc finger; SH3, 
SRC homology 3; UBPY, ubiquitin isopeptidase Y; UEV, ubiquitin E2 variant; UIM, 
ubiquitin? interacting motif; VHS, Vps27, HRS and STAM; Vps, vacuolar protein 
sorting; VSL, VTA1, SBP1 and LIP5; WH2, winged helix 2 
(table taken from (Hurley and Hanson)) 
 
The heterodimer ESCRT 0 consists of hepatocyte growth factor regulated tyrosine 
kinase substrate (Hrs), which is the human homologue of Vps27, and the signal 
transducing adaptor molecules 1 and 2 (STAM 1, STAM 2). Together with the Golgi - 
localised, -ear containing, Arf – binding protein 3 (GGA3), ESCRT 0 binds 
ubiquitinated cargo upstream of ESCRT I and guide ESCRT I, by binding to TSG101, 
to the late endosome (Katzmann et al., 2003; Kirisits et al., 2007; Puertollano and 
Bonifacino, 2004). It was shown that mutations yielding perturbed Hrs/TSG101 
interaction resulted in insufficient transfer of EGFR from early to late endosome 
(Kirisits et al., 2007; Lu et al., 2003). Consequently, treatment of cells with si-RNAs 
targeting GGA3 led to inhibited EGFR degradation (Kirisits et al., 2007; Puertollano 
and Bonifacino, 2004). Additionally, similar results were obtained in Hrs (-/-) and 
STAM1 (-/-)/STAM2 (-/-) mice (Kanazawa et al., 2003; Kirisits et al., 2007), which 
emphasizes the importance of both Hrs/STAM and GGA3 for cargo recognition and 
cargo feeding into the MVB.  
ESCRT I is a heterotetramer comprising one copy each of the subunits Vps23 (in 
mammalians Tumor susceptibility gene 101; Tsg101), Vps28 (hVps28), Vps37A 
(hepatocellular carcinoma related protein 1; HCRP1) and the multivesicular body 
sorting factor 12 (Mvb12) (Chu et al., 2006; Curtiss et al., 2007; Kirisits et al., 2007; 
Kostelansky et al., 2007; Oestreich et al., 2007). The heteotetramer complex is 
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centred around a 13 nm long stalk and a 5nm long headpiece (Hurley and Hanson). 
Vps23 (Tsg101) contains an ubiquitin E2 variant (UEV) domain which binds 
ubiquitinated cargo (Katzmann et al., 2001; Sundquist et al., 2004; Teo et al., 2004b) 
as well as ESCRT 0, whereas the amino terminal basic helix of ESCRT I contributes 
to membrane binding (Hurley and Hanson) .At the end of the stalk another short 
ubiquitin binding domain of Mvb12 is located (Shields et al., 2009), as well as the N-
terminal helix of Vps37A (HCRP1), which is involved in electrostatic interactions with 
acidic membrane lipids (Kostelansky et al., 2007). A GPPXXY motif builds a linker 
between the UEV motif and the stalk. The C-terminal helical domain of Vps28 is itself 
responsible for binding the ESCRT II complex. Separate inhibition of any of the 
ESCRT I subunits by siRNA or antibodies results in stalled EGFR degradation 
(Bishop et al., 2002). Like ESCRT I , the ESCRT II complex is a heterotetramer which 
contains one protein of Vps22 and Vps36 and to molecules of Vps25, which builds a 
rigid Y- shaped core of about 15nm (Hierro et al., 2004; Im and Hurley, 2008; Teo et 
al., 2004a). Vps25 contains two winged helix motif, one at the N-terminus of which 
binds to structurally analogous pockets in the C-terminal motif of Vps22 and Vps36. 
The second, C-terminal winged helix motif binds recruits and activates the upstream 
ESCRT III subunit Vps20 (Im et al., 2009; Saksena et al., 2009; Teo et al., 2004a). 
Vps22 is essential for the membrane recruitment of ESCRT II (Im and Hurley, 2008). 
Remarkably, Vps36 is quite complex in yeast compared to the human analogue 
which has a much simpler architecture. Both Vps36 homologues contain a GRAM- 
like ubiquitin binding in EAP45 (GLUE) domain, which is important for binding 3-
phosphoinositides (and ubiquitin in humans) (Alam et al., 2006; Hirano et al., 2006; 
Slagsvold et al., 2005; Teo et al., 2006). 
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Figure 5: ESCRT complexes I and II; ESCRT I contains multivesicular body sorting 
factor 12 (Mvb12), vacuolar protein sorting 23 (Vps23), Vps28 and Vps37 and 
ESCRT?II consists of Vps20, Vps22, Vps25 and Vps36) 
(figure taken from(Hurley and Hanson)) 
 
ESCRT III is a dynamic polymer that does not have a clearly defined composition of 
proteins. In yeast, ESCRT III contains four main subunits: Vps20, Sucrose non 
fermentor 7 (Snf7), Vps24 and Vps2 (which is also known as DOA4 independent 
degradation protein 4 (Did 4)) (Babst et al., 2002) and regulator subunits Did2, Vps60 
and the increased sodium tolerance protein 1 (Ist 1). The human ESCRT III list 
contains twelve additional proteins, including three isoforms of SNF7 and two DID2 
and two VPS2 proteins which can form alternative complexes. Interaction of ESCRT 
II with Vps20 initiates polymerization of the ESCRT III subunits (Babst et al., 2002; 
Kirisits et al., 2007) whereas the latter complex leads recycling proteins to the site of 
action, like Bro 1 which is required for the recruitment of Doa 4 a deubiquitinating 
enzyme and Vps4, which is the AAA- type ATPase which is responsible for ESCRT 
disassembly (Babst, 2005). The ESCRT III proteins share a common overall 
architecture (Hurley and Hanson) and the common behavior of cycling between a 
closed monomeric state in the cytosol and an open polymerized form on the 
endosomal membrane (Shim et al., 2007; Zamborlini et al., 2006). Intramolecular 
autoinhibition interactions prevent membrane binding and polymer assembly by 
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maintaining the closed cytosolic conformation of each ESCRT III protein. As ESCRT 
III assembles, which is an energetically favorable process, these autoinhibitory 
interactions are deallocated in their “open“ conformation and the subunits bind to 
each other and to the membrane (Hurley and Hanson). 
 
Figure 6: Schematic view of ESCRT III assembly and Vps4 mediated disassembly. In 
the cytosol ESCRT II proteins are in their monomeric “closed” conformation. In their 
“open” conformation ESCRT III subunits bind to each other and to the membrane as 
they assemble into functional ESCRT III polymers. 
(figure taken from(Hurley and Hanson)) 
 
1.7. Membrane budding, scission and MVB formation 
The deformation of the membrane into a bud (a vesicle that is still attached to the 
limiting membrane) is the first step in MVB formation, followed by scission of the 
vesicle. In vitro studies with purified proteins and GUVs showed that recrution of 
ESCRT I together with ESCRT II can lead to bud formation (Wollert and Hurley). 
ESCRT I and ESCRT II led to bud formation even at low concentrations (15 nM) 
compared to ESCRT III subunits Vps20 and Snf7 which can induce bud formation 
only at super-physiological concentrations (600nM for Snf7) (Babst et al., 2002), as 
ESCRT III is actually involved in membrane scission. Additionally, it was shown that 
the two ESCRT complexes I and II localize almost exclusively at the bud neck 
(Hurley and Hanson), as they are involved in the stabilization of the bud neck itself 
(Hurley and Hanson). After bud formation and stabilization by ESCRT I and II, 
ESCRT III is recruited to the membrane in order to additionally stabilize the neck and 
in succession it leads to cleaving of the membrane. ESCRT III subunits assemble at 
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the membrane neck, where Vps20 is required for coupling ESCRT III to ESCRT II (Im 
et al., 2009; Saksena et al., 2009; Teis et al.; Teo et al., 2004a). These strong 
intersubunit and subunit – membrane interactions, which occur as ESCRT III 
assembles at the membrane, provide energy for the scission reaction. Especially the 
strongly favorable electrostatic interactions with the acidic membrane seem to serve 
as parameters whether the energy barrier to scission and the followed release of the 
vesicle can be overcome (Hurley and Hanson). Finally after completion of the 
scission reaction, ESCRT III is disassembled by the AAA+ ATPase Vps4, which 
functions as a ring shaped dodecameric cylinder (Gonciarz et al., 2008; Hartmann et 
al., 2008; Inoue et al., 2008; Landsberg et al., 2009; Scott et al., 2005; Yu et al., 
2008) with highly conserved amino acid residues in the central pore of Vps4 (Scott et 
al., 2005). ATP hydrolysis is the only step in the reaction where energy is put into the 
system, providing the only thermodynamic driving force for ESCRT mediated 
membrane budding and scission (Hurley and Hanson). It is suggested that polymeric 
ESCRT III subunits are pulled into or through the central pore in order to release 
them as monomeric subunits into the cytosol (Gonciarz et al., 2008; Scott et al., 
2005; Yu et al., 2008). This interaction requires additional N-terminal microtubule – 
interacting and transport domains (MIT) with α – helical MIT interacting motifs (MIMs) 
at or close to the C- termini of the ESCRT III proteins (Kieffer et al., 2008; Obita et al., 
2007; Stuchell-Brereton et al., 2007). MIMs are not only required for ESCRT III 
polymer assembly, but also to induce the normally inactive monomers or dimers in 
the cytosol to form a functional Vps4 AAA+ dodectamer. Additionally other proteins 
which bind to Vps4 regulate its oligomeric state and activity. Vta1 binds to Vps4 and 
is involved in its oligomerization, Did2 which functions as a positive and Ist1 which 
functions as a negative regulator and Vps60 which is also involved in Vps4 regulation 
(Hurley and Hanson). 
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Figure 7: Membrane scission by ESCRT III. Vps20 initiates the assembly of ESCRT 
III (Hurley and Hanson); several Snf7 molecules form spiral structures by 
polymerizing downstream of Vps20 (Hanson et al., 2008; Saksena et al., 2009); Vps2 
and Vps24 molecules close the formed spiral; The ESCRT III spiral assembles at the 
bud-proximal side of ESCRT II in order to carry out scission; Vps disrupts ESCRT III 
polymer formation under ATP hydrolysis. (figure taken from Hurley and Hanson) 
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1.8. HCRP1/ hVps37A – a member of ESCRT I 
Originally, HCRP1 was described in yeast (where it is called Vps37A (vacuolar 
protein sorting 37 homolog A) as one of the three subunits of ESCRT I which actively 
drive the sorting away from nonubiquitinated cargo (Conibear, 2002; Katzmann et al., 
2001). In yeast ESCRT I was reported as consisting of the three class E vps 
(vacuolar protein sorting) proteins Vps23, Vps28 and Vps37, which are responsible 
for sorting of ubiquitinated MVB (Bache et al., 2003; Katzmann et al., 2002). The 
human counterpart of Vps37A (hVps37A) was identified to interact with Tsg101 
(human Vps38 homolog) and human Vps28 through its mod(r) domain(Bache et al., 
2004). As the expression of the human homolog of Vps37 A (hVps37A) was shown to 
be undetectable or reduced in hepatocellular carcinoma (HCC) by a positional 
cloning approach (Xu et al., 2003), the name HCRP1 (hepatocellular cancer related 
protein) was suggested. HCRP1 overexpression in a HCC cell line led to reduced cell 
growth in vitro, whereas siRNA mediated reduction of HCRP1 levels resulted in 
inhibited EGFR down regulation and hence increased cellular proliferation (Xu et al., 
2003). 
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Figure 8: A) Domain structure of Vps37 and HCRP1. The most highly conserved 
regions between proteins are shown in gray, which contain a mod(r) domain (modifier 
of rudimentary). Three additional proteins contain this region: hVps37B, hVps37C 
and hVps37D. B) Alignment of the conserved region between Vps37, HCRP1 and 
the rat counterpart of Vps37 and HCRP1. The arrow indicates the start point of the 
mod(r) domain. HCRP1 shows 21% sequence identity (41% sequence similarity) with 
yeast Vps37A in the C-terminal part (Bache et al., 2004; Xu et al., 2003). 
(figure taken from (Bache et al., 2004)) 
 
1.9. HCRP1 in ovarian cancer – therapeutic implications and prognostic 
influence 
As there is a close connection between positive EGFR signaling and human cancer, 
two therapeutic implications have been developed in order to target the EGFR -
pathway. One approach is ATP competitive inhibition of small molecule tyrosine 
kinase inhibitors or targeting the extracellular receptor domain with monoclonal 
antibodies, like Cetuximab, a chimeric monoclonal antibody (Wittinger et al 2011). 
Regarding the impact of altered EGFR signaling and of course its degradation in 
human cancer development, the EGFR degradation pathway and its members 
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display a promising target for future cancer therapy development and prognosis 
(Kirisits et al., 2007). Functional screens for tumor suppressor genes identified TSG 
101 (tumor susceptibility gene 101), a member of ESCRT I, to be able to induce 
malignant development in NIH 3T3 cells (Kirisits et al., 2007; Li and Cohen, 1996), 
similar to HCRP1 which enhances cellular proliferation when knocked down 
(described before). Additionally HCRP1 was shown to be located at the short arm of 
chromosome 8, a region where loss of heterozygosity (LOH) occurs in a high 
percentage of human cancers including ovarian cancer (Pils et al., 2005) which 
makes HCRP1 an attractive target for cancer research and potentially a prognostic 
factor. Krainer and colleges (Wittinger et al 2011) showed that the prognostic value of 
EGFR and HER2 depends on the status of HCRP1 expression. (described in detail in 
Results) This was achieved via a Tissue Micro Array (TMA) of ovarian cancer 
patients, analyzing the co-expression of HCRP1 and EGFR and HER2. 
Overexpression of these two cancer markers was associated with a negative 
outcome for ovarian cancer patients, but this influence on overall survival was only 
observed in cases with low or absent HCRP1 expression (see in detail Results). In 
order to characterize the impact of HCRP1 expression in tumor development, an 
ovarian cancer (cell line) model was used to define its function in vitro and in vivo. 
The results of these experiments are presented in this thesis. 
 
2. Results 
The experiments I performed during my studies as a diploma student and which are 
presented in this thesis build on preliminary experiments performed in the laboratory 
of Professor Krainer. In a previous study, Krainer and colleagues (Kirisits et al., 2007) 
describe the importance of the ESCRT for proper receptor degradation and proposed 
HCRP1 as interesting candidate for further research due to its importance in 
endosomal sorting. As already mentioned, a tissue micro array (TMA) was performed 
in order to confirm a possible correlation of EGFR/HER2 and HCRP1 expression in 
ovarian cancer patients (described in detail below). To further characterize the 
consequences of deregulated HCRP1 expression, an inducible HCRP1 system was 
established. Krainer and colleges used this system to analyze the effect of HCRP1 
knock down on EGFR signaling, anti EGFR antibody treatment (Cetuximab) as well 
29 
 
as the influence on proliferation and invasiveness. My work under this aspect was to 
further investigate the influence of depleted HCRP1 on tumor formation in a mouse 
xenograft model as well to further characterize the HCRP1 knock down in vitro. 
Additionally, I characterized a novel HCRP1 monoclonal antibody and repeated the 
previously performed TMA. Finally, I analyzed HCRP1 expression in cancers other 
than ovarian cancer, confirming the notion that loss of HCRP1 is associated with a 
negative clinical outcome. 
2.1. Growth Factor Degradation – Influence on prognosis and clinical 
outcome - Correlating HCRP1 and EGFR/HER2 levels in ovarian cancer 
As mentioned in the introduction, Krainer and colleagues proposed that HCRP1 
influences the impact of EGFR/HER2 over-expression on the survival rate of ovary 
cancer patients (Pils et al., 2007). Since HCRP1 is involved in endosomal receptor 
degradation and hence influences receptor degradation, a Tissue micro array (TMA) 
of ovarian cancer patients was used to confirm this notion. The TMA was performed 
in order to analyze EGFR, HER2 and HCRP1 expression showing high protein 
expression for the two oncogenes EGFR and HER2, which was also associated with 
a negative outcome for cancer patients. Protein expression was graded according to 
staining intensity (see table 2 and 3; figure 31). Concerning HCRP1 expression, the 
patient cohort was divided into two groups according to their protein expression 
levels. A high percentage of the tumors displayed either low or absent HCRP1 
expression.  
Additionally, in order to confirm the loss of HCRP1 in ovarian cancer patients, an 
independent cohort of ovarian cancer patients was analyzed for HCRP1 expression 
on the mRNA level. It was shown that compared to normal (i.e. epithelial) ovarian 
tissue there is lower expression of HCRP1 in cancer patients. (see figure 29) For 
further confirmation of the prognostic value of HCRP1 the overall survival of the 
patients was stratified based on HCRP1 expression. As a result there was a high 
impact of HER2 as well as EGFR expression on overall survival only for cases with 
low or absent HCRP1 expression, whereas this prognostic aspect is lost in patients 
with regular or high HCRP1 expression. This aspect underlines the possible influence 
of endosomal receptor degradation on clinical relevance of growth factor expression. 
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Figures and tables are given below (see “HCRP1 in Ovarian cancer patients – Tissue 
Micro Array analysis”). 
 
2.2. Molecular analysis of HCRP1 function by gene knock-down 
2.2.1. A system for the inducible down - regulation of HCRP1 
To mechanistically analyze the role of HCRP1 in vitro and in vivo, an inducible 
shRNA system (tet - Off) was established in Skov3 ovarian cancer cells (described in 
detail in Materials and Methods). Silencing effectiveness is given in figure 9 (Western 
Blot) and Figure 10 (qRT PCR). 
2.2.2. Stable knock down of HCRP1 in MDAH-2774 cells  
In addition to the inducible system, another ovarian carcinoma cell line, MDAH 2774, 
was stably transfected with a shRNA construct in order knock-down HCRP1. 
Silencing effectiveness is given in figure 26 (Western Blot) and figure 27 (IHC). 
 
Figure 9: Skov3 tet cells were cultivated with Dox or PBS in order to gain HCRP1 
knock down and were analyzed by SDS – PAGE. Silencing of HCRP1 leads to an 
increase in HER2 and EGFR phosphorylation. 
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Figure 10: mRNA level of Skov3 cells and Skov3 tet cells treated with PBS/ DOX 
(1µ/µl). The figure shows shRNA mediated knock down of HCRP1 in Skov3 cells 
when DOX is removed from the media.  
 
Analysis of the previously described cells lines revealed that both the transfected 
Skov3 and MDAH-2774 cells showed remaining HCRP1 expression of 30-40% 
(measured by qRT PCR; results shown in figure 10; data for MDAH cells not shown). 
In addition and consistent with the loss of HCRP1 activity, these cells displayed 
elevated levels of activated EGFR and HER2. Interestingly, juxtaposing HCRP1 
expression with activated EGFR levels showed that only phosphorylated EGFR was 
elevated whereas normal EGFR levels stayed constant (see figure 9) and an 
increase of the pEGFR/EGFR ratio. This finding implicates that activated EGFR 
accumulates in cells with decreased HCRP1 expression due to disrupted EGFR 
degradation. Furthermore, immunofluorescence analyses were used in order to 
detect the localization of the retained pEGFR within the cells. These experiments 
demonstrated that whereas pEGFR was hardly detectable in control cells, in HCRP1 
knock-down cells pEGFR was localized at high levels in the cytoplasm (see figure 
11). Interestingly a frequent co -localisation with the early endosomal marker EEA1 
was detectable, (see figure 11) which indicates that pEGFR accumulates mainly in 
sorting endosomes. This further underlines the effect of disrupted EGFR sorting in 
HCRP1 depleted cells.  
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Additionally an immunoblot analysis was done to quantify HCRP1, (p) EGFR and (p) 
HER2 in 15 ovarian and breast cancer cell lines. There was no significant correlation 
between HCRP1 and EGFR but a quite clear reciprocal correlation between HCRP1 
and pEGFR. On the other hand, there was only a statistically weak correlation 
between HCRP1 and HER2 protein expression. This data additionally underscore 
that phosphorylated EGFR accumulates in ovarian cancer cells due to defect 
endosomal protein degradation. To study the dynamics of pEGFR degradation in wild 
type and HCRP1 knock down cells, the cell lines were incubated in serum free 
medium followed by stimulation with 100ng/ml EGF for 15min in order to trigger 
receptor activation, which was followed by re-incubation in serum free medium. Cells 
were harvested at defined time points and pEGFR protein expression measured by 
Western Blotting (see figure 12). Degradation of pEGFR was significantly impaired in 
HCRP1 deficient cells, whereas total receptor levels remained constant in both 
SKOV3 and MDAH-2774 cells, which suggests sustained EGFR signaling in these 
cell lines.  
 
Figure 11: pEGFR (red) accumulates in HCRP1 silenced cells and is colocalized with 
early endosomal marker EEA1, (blue). SKOV3tet off cells were cultivated in presence 
or absence of doxycycline on chamber slides, probed against pEGFR and EEA1 and 
analyzed by confocal microscopy. Colocalization of the pEGFR (red) and EEA1 
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(blue) signal is indicated by arrows. Green fluorescence of the nuclei arises from the 
presence of an EGFP cassette in the Tet-Off vector. 
 
 
Figure 12: SDS – PAGE showing that time-pulsed activation of pEGFR is sustained 
in HCRP1 silenced cells. SKOV3tet off cells cultivated in presence or absence of 
doxycycline were starved by serum withdrawal, then pulsed with 100ng/ml EGF and 
cultivated for indicated time in serum-free medium.  
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2.3. HCRP1 – influences on EGFR signaling and anti EGFR antibody 
treatment 
To test the effect of HCRP1 knock-down on downstream EGFR signaling HCRP1 the 
inducible HCRP1 knock down system was used. Knock-down of HCRP1 led to 
increased phosphorylation of Erk1/2, consistent with extensive receptor 
phosphorylation and downstream pathway activation. Akt phosphorylation at serine 
473 was not changed in the two studied cell lines.  
The next step was to test the effect of the anti-EGFR antibody Cetuximab and the 
EGFR/HER2 inhibitor Lapatinib on EGFR phosphorylation in HCRP1 knock-down 
cells. After Lapatinib treatment, EGFR signaling was inhibited in both wild type and 
HCRP1 knock down cells, shown by the dephosphorylation of Erk1/2 and Akt in both 
Skov3 and MDAH 2774 cell lines. In contrast, Cetuximab treatment of HCRP1 knock 
down cells caused Erk1/2 and Akt to stay phosphorylated, which suggests the 
importance of cytoplasmatic EGFR degradation for Cetuximab dependent inhibition 
of its downstream pathways. On the other hand, Lapatinib mediated EGFR inhibition 
seems to be mediated by its direct interaction with the tyrosine kinase domain, which 
is independent of endosomal processing and hence unaffected by HCRP1 status.  
 
2.4. Defective activation of Erk-signaling leads to increased cellular 
proliferation, invasion and tumorgenesis in HCRP1 knock-down cells 
The comparison of Skov3 control cells with HCRP1 knock-down cells regarding their 
doubling times (25,5 and 24,9 hours) revealed that there was only a very moderate 
impact of HCRP1 knock-down on cellular proliferation under unstressed in vitro 
conditions. However, after incubation with Cetuximab there was a significant 
decrease of the proliferative potential in cells expressing HCRP1 compared to 
HCRP1 knock-down cells, which remained unaffected. This emphasizes the notion 
that the presence of HCRP1 is crucial for proper degradation of the receptor - 
antibody – complex, which is further essential for proper cetuximab mediated anti–
tumor activity (Wheeler et al., 2008). Treatment with Lapatinib reduced cell 
proliferation independent of HCRP1 expression levels. 
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Figure 13: HCRP1 silenced cells are resistant to cetuximab. 2x105 SKOV3tet off cells 
were cultivated in presence or absence of doxycycline and exposed to 20μg/ml 
cetuximab, or 4μM lapatinib or remained untreated. Cell number was determined 
every 48 hours by a CASY cell counter over 8 days. Doubling time (dt) was 
calculated, normalized to untreated control and depicted as 1/dt. The columns 
indicate the mean of three independent experiments 
 
 
Figure 14: hVps37A silencing leads to resistance against cetuximab mediated EGFR 
inhibition. SKOV3tet off cells cultivated in presence or absence of doxycycline were 
incubated for 24 hours with either 20μg/ml cetuximab, or 4μM lapatinib or remained 
untreated. Protein levels of pAkt, Akt, pErk1/2, Erk1/2 and actin  
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2.5. HCRP1 knock down increases invasive potential of tumor cells 
 
To mimic physiological tumor growth conditions, Skov3 cells were seeded into non 
adhesive 96 – well plates containing methylcellulose complemented media in order to 
generate tumor- like spheroids of several hundred cells. These spheroids were 
transferred to 3D culture - collagen gels and incubated for 72h. The overall growth 
rate was not affected by HCRP1 expression, however HCRP1 knock-down cells 
could invade the collagen matrix more efficiently (see figure 15), which underlines the 
impact of HCRP1 on the invasiveness of cancer cells rather than their proliferation. 
The invasive potential was calculated as percentage of outgrowing cells relative to 
the central area of the spheroid (73, 5 % compared to 30% for the control cells). 
 
Figure 15: (A) shows Skov3 tet cells cultivated in presence or absence of doxycycline 
in a collagen matrix. Spheroids were analyzed by light microscopy. (B) shows the 
area of outgrowing cells depicted in percentage relative to central spheroid. Error 
bars indicate mean +/- SEM. 
 
Additionally we performed a wound healing assay by simply cultivating Skov3 tet 
cells which were treated with PBS (induced HCRP1 knock down) or Dox and 
scratched them with a spatula.  We could observe a clear difference between the two 
cell lines as HCRP1 knock down in Skov3 tet PBS treated cells led to enhanced 
proliferation and hence better “wound” healing ability. 
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Figure 16: A wound healing assay with Skov3 tet cells was performed in order to see 
the effect of HCRP1 knock down on stress induced proliferation. Cells were plated on 
cell culture dishes and scratched with a spatula. The cells were treated with Dox 
(HCRP1 (+), left) or PBS (HCRP1 (-), right) and incubated for 24 hours. HCRP1 
knock down led to significantly enhanced proliferation. 
 
2.6. A mouse Xenograft model shows enhanced tumor growth in HCRP1 
silenced tumors 
A mouse Xenograft model was used to address the effect of HCRP1 down -
regulation in tumor formation caused by hyperactivation of EGFR due to the lack of 
proper receptor degradation. Two cell lines were subcutaneously injected into nude 
mice: the Skov3 ovarian cancer cell line as a control and additionally the Skov3 cell 
line with the inducible shRNA tet-Off system in order to down - regulate HCRP1 when 
cells/mice are not treated with Doxycycline (DOX). Effectiveness of the inducible tet 
system is given in figure 10.  
Before the Skov3 and Skov3 tet cells were injected into mice a PCR (Venor ® GeM; 
Minerva biolabs) was performed in order to detect mycoplasma in cells (see figure 
17). We used cells from bottles number 3, 4 and 6 for further cultivation and injection. 
 5 x 106 cells were subcutaneously injected into four eight week old Foxn1nu mouse 
groups with 10 mice each. The groups were treated either with PBS or DOX which 
were injected into the flanks of mice. Tumor size was measured weekly. In line with 
the in vitro results, HCRP1 knock-down tumor growth was elevated resulting in mean 
tumor volumes of 1027mm3 compared to 683mm3 for the un-induced tumors. The 
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tumors started to grow after seven days whereas both Skov3 tet PBS and Dox 
treated tumors showed almost equal growth. After four weeks there was a significant 
difference in tumor growth observed between the two groups. In week six and seven 
tumors started getting necrotic hence mice had to be sacrificed. The mice were 
sacrificed according to the institutional ethics committee protocols, tumor samples 
were frozen in liquid Nitrogen and the rest was embedded in paraffin.  
The successful knock-down of HCRP1 was confirmed via IHC staining of mouse 
tumor samples (see figure 20). Also, significantly decreased apoptosis rates for the 
HCRP1 knock down tumors were observed. This indicates that the tumor growth 
effect can be ascribed to sustained survival rather than elevated proliferation. 
Problems occurred during the detection of HCRP1 mRNA and protein levels from 
mouse tumors extracts (discussed in detail later). 
Control groups with injected Skov3 cells were also treated with PBS and DOX. There 
was no difference in growth observed between the two mouse groups, indicating that 
DOX treatment does not influence tumor growth. Interestingly tumors originating from 
these cells grew much slower compared to tumors arising from Skov3 tet cells with 
the inducible HCRP1 knock down system. This might be caused by several reasons: 
1) the cells could have been in bad shape at the time of injection, 2) the induction of 
the inducible system might cause the cells to gain enhanced proliferation ability and 
3) the inducible tet system was leaky which led to reduced HCRP1 levels even in 
Skov3 tet cells treated with Dox. Though, immunhistochemical staining of Skov3 tet 
tumor samples showed a clear difference. The same was true for mRNA level 
detected with qRT PCR protein expression level and protein level, analyzed with 
Western blotting (data not shown) of the Skov3 (tet) cells before injection. These 
findings confirm that the inducible tet system was working properly before injection 
and in the mouse experiment. 
Further analysis of the used cell lines is described and discussed below. Analysis of 
HCRP1 protein levels extracted from mouse tumor samples did not lead to satisfying 
results as there was no reasonable difference observed between the samples. 
HCRP1 bands were smeary and additional bands appeared when blotting protein 
samples from mouse tumors. (see figure 25) mRNA level measurement with qRT 
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PCR also did not lead to satisfying results (see figure 17). Although we could observe 
HCRP1 knock down in Skov3 tet cells, the HCRP1 mRNA level measured for Skov3 
cell tumors was very low compared to Skov3 tet cells both with induced and un - 
induced HCRP1 knock down. Both problems with Western Blotting and qRT PCR 
presumably result from problems with protein and RNA extraction. For extraction of 
both RNA and protein I crushed the tumor samples (which were frozen in liquid 
nitrogen before) with a mortar for tissues and used the same protocol I used for 
protein and RNA extraction of cell line cells. As the protocol worked very well for 
extraction of cells from cell culture I assume that either the procedure of extracting 
was not sufficient due the tumor was not grounded sufficiently or, especially 
concerning RNA extraction, the sample was contaminated with extracellular protein. 
Currently I am aim to establish a proper RNA and protein isolation protocol.  
 
 
Figure 17: PCR for mycoplasma detection. Skov3 and Skov3tet cells were tested for 
mycoplasma. Cells from bottles number 3, 4 and 6 were used for further experiments. 
Numbers indicate cell culture bottle numbers; marker (M). 
1 2 3 4 5 6 7 8 M 
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(A) 
 
(B) 
 
Figure 18: (A) In vivo growth of HCRP1 knock-down cells. Tumors arising from 
HCRP1 knock-down Skov3 cells showed elevated growth compared to un - induced 
Skov tet cells. Relative tumor growth (x-fold volume initially measured) is depicited 
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against time (days). Tumor growth was measured weekly. (B) Control mice with 
injected Skov3 cells treated with PBS/DOX did not show elevated growth.  
 
 
Figure 19: qPCR analysis of HCRP1 mRNA levels of mouse xenograft tumors 
resulting from injected Skov3 - and Skov3 tet cells treated with PBS/ DOX (1µ/µl) 
(Skov3 (tet) mt). PBS treatment of mice with injected Skov3 tet cells should induce 
HCRP1 knock down whereas HCRP1 levels of tumors originating from Skov3 (PBS 
and Dox treated) and Skov3 tet Dox treated cells should be about the same. This is 
true for Sko3 tet cells treated either with Dox or PBS, although the observed knock 
down was not as significant as it was shown in in vitro experiments with Skov3 and 
Skov3 tet cells before (see Figure 10). HCRP1 mRNA levels of Skov3 PBS and Dox 
treated cells were quite low which might result from problems with mRNA isolation.  
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(B) 
 
Figure 20: Formalin paraffin – embedded mouse tumor (subcutaneously injected 
Skov3tet cells, sections were immunostained with the HCRP1 specific monoclonal 
antibody. Tumors from mice treated with DOX (125µg/day) showed normal (HCRP1 
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(+)) HCRP1 levels whereas PBS treated mice should displayed reduced HCRP1 
expression (HCRP1 (-)). (A) shows stainings from mice treated with DOX (left) and 
PBS (right) with corresponding control staining where no antibody was used. 
Magnification 10x (B) shows stainings from mice treated with DOX (left) and PBS 
(right). Magnification 40x 
 
In the tumors arising from the xenografts, cellular proliferation was not significantly 
affected as determined by a Ki67 assay (see figure 21). However there were 
significantly decreased apoptosis rates for the HCRP1 knockdown tumors (see figure 
22). Hence this suggests that enhanced tumor growth can be explained by sustained 
survival rather than by elevated proliferation. 
 
Figure 21: (A) Ki-67 stainings in the mouse xenograft model. The left panel shows 
representative Ki-67 stainings (magnification 10x and 40x). The right panel shows a 
quantitation (percentage) of Ki-67 cells. Error bars indicate +/- SEM.  
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Figure 22: Average counts of apoptotic cells in tumors examined. Error bars indicate 
+/- SEM. 
 
2.7. Challenging titration of a novel monoclonal HCRP1 antibody  
Preliminary experiments were performed with a polyclonal HCRP1 antibody. After 
selecting the following peptide sequence MSPYASQGFPFLPPY a monoclonal 
antibody against this peptide was produced and affinity purified by Eurogentec 
(Seraing, Belgium). TMA stainings were repeated with the new antibody (described 
below). Mouse Xenograft tumors, Skov3 HCRP1 knock down cells and MDAH – 2774 
cells were stained with the novel antibody. Multiple staining conditions have been 
tested in order to get an optimized and reproducible protocol. Figure 23 shows 
different staining protocols with either too high ((A) 1:500) or too low ((B) 1:2000) 
antibody concentration. Figure 29 shows results of the TMA stained with the finally 
established protocol. 
. 
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(B) 
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Figure 23: (A) Titration of the monoclonal HCRP1 antibody. Pictures show examples 
of a TMA staining attempt which was over - stained (used antibody concentration: 
1:500). Not a single slide showed negative staining and there was no negative 
control. (B) Pictures show examples of a TMA staining attempt which was stained to 
weak (used antibody concentration: 1:2000). There was not a single slide which 
showed strong epithelial staining. Some slides were absolutely negative. 
 
Antibody titration for Western blotting was quite more challenging. Several antibody 
concentrations were tested in order to establish a reproducible protocol (data not 
shown). Also various and long washing steps especially between first and second 
antibody were crucial in order to avoid strong background signals (further details see 
Materials and Methods). Unfortunately although the antibody eventually gave clear 
and strong HCRP1 signals, there was no clear difference observed between the 
various Skov3 cells with the inducible HCRP1 knock down system (discussed in 
detail below). HCRP1 protein detection by Western Blotting from mouse xenograft 
tumors did not show reasonable results, as there was no coherent difference 
between the samples and bands were smeary (discussed in detail below; see Figure 
25). On the other hand, MDAH – 2774 cells with stable HCRP1 knock down showed 
clear differences in HCRP1 protein level compared to MDAH – 2774 “wild type” cells 
(see Figure 25; 26; 27). This suggests that detection difficulties of HCRP1 knock 
down in Skov3 tet cells is not only caused by problems with the novel established 
protocol but due to problems with the inducible tet off – system. Further protocol 
establishment and inducible tet – system analysis is discussed below in “HCRP1 
protein and mRNA detection in Skov3 cells with inducible HCRP1 knock down 
system – Challenges and trouble - shooting”. 
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Figure 24: Western blot of Skov3 and Skov3 tet cells treated with PBS/DOX 
(numbers indicate used Dox concentration 1µ/µl etc.). For this WB the finally 
established protocol has been used. Upper line shows HCRP1 expression, bottom 
line corresponding actin detection. Although the established protocol resulted in a 
clear signal, there was no difference observed between the different samples. 
 
(A) 
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(B) 
 
Figure 25: Western Blot with the monoclonal HCRP1 antibody showing no clear 
difference between Skov3 tet PBS and Dox cells due to problems with the inducible 
HCRP1 system. MDAH cells with stable knock down of HCRP1 show reduced protein 
expression. Mouse tumor tissue samples show smeary bands. This figure shows WB 
with Skov3 and Skov3 tet cells treated with PBS/DOX (numbers indicate used Dox 
concentrations 1µ/ml etc.), MDAH cells and Skov3/Skov3 tet cells from the mouse 
xenograft model (A) and (B). 
 
Figure 26: WB with HCRP1 antibody of Skov3, Skov3 tet (cell batches (a) and (b)) 
and MHAD- 2774 A cells with stable HCRP1 knock down. There is a clear difference 
between the Skov3 cells and MDAH knock down cells and a weaker but clear 
difference between Skov3 (PBS) cells, Skov3 tet PBS (with HCRP1 knock down) and 
Skov3 tet DOX cells, whereas the difference between Skov3 tet PBS and Skov3 tet 
Dox (b) is stronger than compared to batch (a). 
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Figure 27: Western Blott with HCRP1 monoclonal antibody, showing prober knock 
down in stabely transfected MDAH cells (MDAH A and MDAH C, are both stabely 
transfected cells, but derive from different clones). 
 (A) 
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(B) 
 
Figure 28: IHC of MDAH (normal HCRP1; middle picture) and MDAH (HCRP1 knock 
down; right picture) cells with stable HCRP1 knock down with HCRP1 monoclonal 
antibody; used dilution 1:5000, magnification 10x (A) and 40x (B), The left picture 
displays the negative control without antibody. 
 
2.8. HCRP1 protein and mRNA detection in Skov3 cells with inducible HCRP1 
knock down system – Challenges and trouble - shooting 
As mentioned above, several problems occurred during titration of the novel 
monoclonal HCRP1 antibody. Figures 25 -28 show several WB with Skov3 (PBS and 
Dox treated), Skov3 tet (PBS and Dox treated) and MDAH – 2774 “wild type” and 
knock down cells. Skov3 cells were cultivated with Dox or PBS in order to see if Dox 
influences HCRP1 expression in general. It was shown that neither protein level, nor 
HCRP1 mRNA level were influenced by Dox treatment. MDAH – 2774 cells with 
stable HCRP1 knock down showed a clearly reduced HCRP1 protein level. This 
suggests that problems which occurred with the inducible HCRP1 system in Skov3 
tet cells is not caused by technical problems. One possibility is the fact that the cells 
used for protein and RNA extraction were kept in culture for too long. Multiple cell 
passages and constant HCRP1 knock down caused by insufficient Dox treatment can 
lead to altered gene expression and hence potential compensatory mutations. I 
tested various Doxycycline concentrations of 0,5; 1; 2; 3; 6 and 12 µg/µl (data for 
concentrations 0,5; 2 and 6 µg/µl not shown) which did not cause different HCRP1 
protein levels. As a result I thawed fresh aliquots of cells and repeated the 
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experiments. This time qRT PRC results for HCRP1 in Skov3 (tet) cells led to 
reasonable results, showing significant HCRP1 knock down (as previously shown in 
figure 10). This finding confirms proper HCRP1 knock down in Skov3 tet cells. 
HCRP1 detection by WB is still challenging, also regarding the fact that stripping of 
the membrane and following Actin antibody staining hardly led to satisfying results as 
there was always a high background signal (figures not shown). Currently I am 
further improving the Western blot protocol. 
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2.9. HCRP1 in Ovarian cancer patients – Tissue Micro Array analysis 
As standards for our tissue micro array, ovarian tissues with normal epithelium were 
taken as positive controls and tissues stained without primary antibody were taken as 
negative control. It was observed that the normal ovarian epithelium showed specific 
positive HCRP1 expression while no staining was seen in the negative control (see 
figure 29). 
  
Figure 29: Immunhistochemical staining of ovarian tissue with the HCRP1 
monoclonal antibody staining with the HCRP1 monoclonal antibody, left negative 
control, right brownish staining of epithelial structure (magnification 40X). 
After titration of the novel HCRP1 antibody and establishment of a proper protocol 
TMAs were stained with the new antibody. The TMAs comprising 125primary tumor 
samples and 19 borderline tumors spotted in triplicates with corresponding normal 
tissue were previously stained with EGFR and HER2 as these two receptors 
represent well known markers in ovarian cancer. Representative stainings are given 
below.  
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Figure 30: Tissue microarrays of 125 primary ovarian tumor samples and 19 
borderline tumors, with corresponding normal tissue were stained for EGFR and 
HER2. Stainings were graded according to their intensity: 0 (absent); 1 (low), 2 
(moderate) and 3 (strong). 
 
As shown by others before (Pils et al., 2007) elevated expression of these 
oncogenes is associated with negative outcome for patients and their overall survival 
rate (data not shown). According to their HCRP1 expression patients were 
subdivided into two groups, whereas a quite high percentage of patients (62%) 
showed low or missing HCRP1 expression (see table 2 and 3). Representative 
HCRP1 stainings graded according to their intensity are given below. 
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Figure 31: Tissue Micro array of 125 primary ovarian tumor samples and 19 
borderline tumors, with corresponding normal tissue were stained with HCRP1 
antibody. Staining intensity was determined on a scale of 0 to 3, with 0 for “negative”, 
1 for “weak”, 2 for “moderate” and 3 for “strong” staining. (magnification40X) 
Comparing HCRP1 mRNA levels of an “independent cohort” of 115 ovarian cancer 
patients (PT) and 20 age matching controls (N; normal) showed lower expression in 
ovarian cancer when compared normal ovarian tissue. 
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Figure 32: Quantification of HCRP1 expression in ovarian tissue micro arrays 
percentage of hVps37A positive cases in the benign (N) and ovarian cancer (PT) 
tissues 
 
 
 
Figure 33: hVps37A mRNA expression in tumor tissue of 115 ovarian cancer patients 
(PT) and 20 age matched normal controls (N); a Student’s t-test was used to 
compare mean mRNA expression levels of hVps37A. 
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Table 2 Tissue Microarray RNA 
Patients’ characteristics N (percent) N (percent) 
Type   
Normal ovaries  20  
Primary tumors 125  115  
Recurrent tumors   
Borderline tumors 19  
Grade 117 (8 missing)  114 (1 missing) 
1 20 (17.1) 3 (2.6) 
2 26 (22.2) 52 (45.6) 
3 71 (60.7) 59 (51.8) 
FIGO 125 113 (2 missing) 
I 31 (24.8) 19 (16.8) 
II 14 (11.2) 10 (8.9) 
III 72 (57.6) 59 (52.2) 
IV 8 (6.4) 25 (22.1) 
Histology 125 115 
Serous 70 (56.0) 70 (60.9) 
Non-serous 55 (44.0) 45 (39.1) 
 
Table 3                 Immunohistochemical staining 
hVps37A No of Patients 
high 55 
low 89 
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 hVps37A 
 high low 
EGFR 
high 39 44 
low 16 45 
HER2 
high 14 25 
low 41 64 
Grade 
1 8 12 
2 11 15 
3 30 41 
FIGO 
I 14 33 
II 7 7 
III 31 44 
IV 3 5 
Histology 
Serous 29 41 
Non-serous 24 31 
 
2.10. HCRP1 expression in pancreatic, lung and oral cavity cancer 
As a next step I looked at HCRP1 expression in pancreatic (figures not shown), lung 
and oral cavity cancer in order to see if individual patients express different levels of 
HCRP1. I could observe varying HCRP1 expression levels in all three kinds of 
cancer. Figure 34 shows representative stainings of two lung cancer patients. 
Samples from patient number one display almost negative stromal staining, whereas 
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the tumor shows moderate HCRP1 expression. In contrast patient number two shows 
strong HCRP1 staining in tumor and stromal tissue.  
(A) 
 
 
(B)  
 
Figure 34: HCRP1 stainings of lung cancer patient tissue. (A) Patient number one 
shows moderate HCRP1 staining in the tumor and almost negative stromal staining. 
The lower picture shows stained epithelial structure. (B) Patient number two shows 
strong HCRP1 expression in both tumor and stroma. 
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A cohort of 111 oral cavity cancer patients was analyzed for their HCRP1 expression 
using Immunhistochemestry. Figure 35 shows representative stainings of samples 
with staining intensities weak (1), moderate (2) and strong (3). As a result 18% of the 
analyzed patients showed weak HCRP1 expression. Interestingly these patients 
displayed a more negative clinical outcome when compared to patients with normal 
or high HCRP1 expression (statistical data not shown) confirming previous findings 
that low HCRP1 expression is linked to a more negative course of disease.  
(A) 
 
3  2
1 
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(B) 
 
 
Figure 35: HCRP1 stainings of oral cavity cancer patient tissue. (A) shows 
representative stainings with weak (1), moderate (2) and strong (3) HCRP1 staining 
intensity in tumors. (B) shows weak (1), moderate (2) and strong (3) HCRP1 staining 
of epithelial structures. Arrows indicate ducts.  
 
 
3. Discussion 
Deregulated activation of ErbB family growth factor receptors is associated with 
tumor development due to enhanced cell proliferation and invasiveness. As this 
hyperactivation is often a result of dysfunctional receptor degradation, the ESCRT 
complex member HCRP1, which is crucial for proper receptor degradation via 
endosomal sorting, is a promising target for anti cancer therapy. Upon ligand binding 
RTKs are phosphorylated at distinct residues located in their cytosolic domains. 
Interestingly, receptors targeted for ESCRT mediated degradation are still capable to 
3  2 
1 
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continue signaling due to the cytosolic orientation of the phosphorylated tail 
structures. This effect is probably even further increased by the cytoplasmatic 
retention of pEGFR (Pennock and Wang, 2003). We observed elevated levels of 
ErK1/2 in HCRP1 knock down cells, whereas basal Akt phosphorylation remained 
unchanged. This may result from the fact that pEGFR located in the endosome is not 
able to activate PI3K signaling whereas other pathways stay unaffected (Haugh and 
Meyer, 2002).  
The EGFR family is a key therapeutic target in many kinds of cancer, including 
ovarian cancer and holds great promise for personalized cancer treatment, as the 
main goal in personalized medicine is to target the individual underlying molecular 
and biological deficiencies of a patient. Two types of inhibitors are currently used in 
clinical trials treating ovarian cancer, monoclonal antibodies (mAb) and small 
molecule tyrosine kinase inhibitors (TKI) (Arteaga, 2002; Palayekar and Herzog, 
2008; Siwak et al.). Due to their low efficiency in phase I and II trials (Kimball et al., 
2008; Sheng and Liu), the application of several therapies targeting EGFR has been 
limited. As the loss of HCRP1 leads to enhanced selective advantages in tumor cells, 
these cells could be more sensitive to EGFR targeted therapy by the usage of mAb 
and small TKI. Cetuximab, an IgG1 monoclonal antibody targeting EGFR, has been 
extensively studied in ovarian cancer but was shown to be ineffective in several 
phase II trials (Konner et al., 2008; Schilder et al., 2009; Siwak et al.). Some other 
TKIs and MAbs (erlotinib, matuzumab, trastuzumab, pertuzumab, CI-10337) used in 
ovarian cancer studies have also yielded disappointing response rates of 0–7% 
(Konner et al., 2008). Cetuximab was shown to inhibit EGFR signaling by competing 
with endogenous ligands, resulting in stalled cellular growth and division as well as 
angiogenesis, invasiveness and metastasis (Fan et al., 1993; Konner et al., 2008; 
Petit et al., 1997; Prewett et al., 1998). Another mechanism to interfere with EGFR 
activity, is antibody dependent cellular cytotoxity (ADCC), which is an immune 
response against the Fc - region of antibodies (Peipp et al., 2008).  
The inhibitory effect on EGFR signaling by Cetuximab is abolished by loss of HCRP1. 
Resistance to anti EGFR therapy can be caused by several mechanisms including 
autocrine EGR activation, mutation of downstream signaling effectors and cross 
activation of alternative RTKs. It was shown that cells resistant to cetuximab 
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expressed elevated levels of steady state EGFR secondary to alterations in 
trafficking and degradation as well as an elevated activation of HER2, HER3 and 
cMET. Additionally, enhanced EGFR expression led to increased dimerization with 
HER2 and HER3 followed by their transactivation, whereas blockage of EGFR and 
HER2 caused loss of HER3 and stalled PI(3)K/Akt activity (Wheeler et al., 2008). 
Studies in Cetuximab resistant cancer cell lines after long term exposure showed 
increased EGFR levels resulting from dysfunctional receptor degradation (Wheeler et 
al., 2008).  
Our HCRP1 knock-down system, which showed Cetuximab resistance, confirmed 
this study and is hence a potential model for pre-existing Cetuximab resistance in 
advanced ovarian cancer. In HCRP1 knock-down cells treated with Cetuximab, the 
MAPK – and Akt- pathway remained active, compared to cells treated with Lapatinib 
where the MAPK – and PI3K/Akt pathways are inhibited. This indicates that the 
EGFR- Cetuximab complex is still actively signaling, resulting in resistance to 
Cetuximab, whereas Lapatinib directly blocks EGFR activation by targeting the ATP – 
binding domain, leading to abolished EGFR signaling independent from ESCRT 
mediated receptor down regulation (Xia et al., 2002) and hence HCRP1 expression.  
An important step was the generation and characterization of the novel and improved 
monoclonal HCRP1 antibody in order to establish reproducible protocols for further 
research. During this process I unfortunately observed that although I could detect 
clear HCRP1 signals in immunoblotting experiments, there was no strong difference 
between cells with or without HCRP1 knock-down. In line with the protein data, 
HCRP1 mRNA levels quantified with qRT PCR equally led to such results. Possible 
explanations for this could be that either the inducible system got leaky or that the 
cells had been in culture for too long leading to a change in gene expression. I also 
tested different Doxycycline (Dox) concentrations in order to observe the influence of 
various levels of Dox treatment on the inducible tet system - still I could not detect a 
clear HCRP1 knock-down. Interestingly, immunhistochemical staining showed 
reasonable results, displaying clear differences between xenograft tumor samples 
(tumors from injected Sov3 (tet) cells) and MDAH – 2774 “wild type” and knock-down 
cells. This indicates that the monoclonal HCRP1 antibody is working properly for 
stainings, suggesting that problems with RNA and protein sample preparation might 
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have caused detection problems. In line with this, freshly thawed cells showed 
reasonable and significant HCRP1 knock-down measured on mRNA level by qRT 
PCR, confirming that the inducible system is working properly. Though there have 
still been problems with HCRP1 detection with Western Blotting and this discrepancy 
between mRNA and protein levels on the one hand, and differences in protein 
detection between IHC stainings and western blotting using the same antibody will be 
addressed in future experiments. The results presented in this thesis demonstrate 
that loss of HCRP1 leads to enhanced invasive potential of cells in vitro and 
increased tumor growth in vivo. 
I used the Inducible HCRP1 system in order to observe the impact of HCRP1 knock 
down on tumor formation in a mouse xenograft model. Mouse groups with injected 
Skov3 tet cells displayed a significant difference in tumor growth. This certifies our 
thesis that HCRP1 knock down enhances tumor growth in vivo. Two mouse groups 
with injected Skov3 cells (treated with PBS or DOX) served as control groups to see 
a possible effect of Dox treatment on tumor growth in general. Both control groups 
showed equal growth suggesting that there is no effect on tumor growth in general. 
As a next step additional mouse experiments including groups treated with 
Cetuximab and TKI would be required to strengthen our finding that the inhibitory 
effect on EGFR signaling by Cetuximab is abolished by HCRP1 knock down. As 
determined by a Ki67 assay cellular proliferation of tumors was not significantly 
affected, however tumors with HCRP1 knock down displayed significantly decreased 
apoptosis rates. These findings assume that enhanced tumor growth is caused by 
sustained survival rather than elevated proliferation.  
Additionally, we could also observe that HCRP1 protein expression levels are often 
reduced in primary ovarian tumors. Overall, EGFR is overexpressed in 60% of 
ovarian cancers (Dimova et al., 2006; Lin et al., 2009) and this is associated with 
poor clinical outcome for ovarian cancer patients (Sheng and Liu; Siwak et al.). 
Furthermore it was shown that stimulation of human ovarian cancer cell lines with 
EGF resulted in significantly increased expression of proteins involved in invasion 
and altered signaling of pathways associated with angiogenesis (Henic et al., 2006; 
Liu et al., 2006). We found that HCRP1 has a strong impact on the prognostic value 
of EGFR and HER2; while both of these oncogenes can be highly accurate 
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prognostic markers this is actual only the case when HCRP1 is highly expressed. In 
contrast under conditions of low HCRP1 expression this prognostic value is lost. 
Therefore, further analysis of HCRP1’s role as a novel player in EGFR and HER2 
mediated ovarian cancer holds great promise for personalized cancer treatment and 
prognosis. 
As already mentioned, hyperactivation of EGFR and dysfunctional receptor 
degradation is found in many kinds of cancer (Holbro et al., 2003; Hynes and Lane, 
2005; Sibilia et al., 2007; Yarden, 2001). Stained Tissue micro arrays for HCRP1 
expression show that HCRP1 levels are elevated compared to normal ovarian tissue. 
We further observed that there is a strong impact of the two cancer markers EGFR 
and HER2 on the overall survival of ovarian cancer patients but only in cases with 
normal (high) HCRP1 expression. This prognostic value is lost in patients with low 
HCRP1 knock down. As a step beyond ovarian cancer, we looked at HCRP1 
expression and addressed possible correlations between protein expression level 
and clinical outcome and prognosis in different kinds of cancer. Therefore we tested 
HCRP1 expression among several patients with pancreatic, lung and oral cavity 
cancer. We found a significant difference in HCRP1 expression levels between 
patients in all three kinds of cancer. To verify the previous findings, biopsies of a 
cohort of 101 oral cavity patients were analyzed concerning their HCRP1 expression 
by immunhistochemestry. As a result 18, 9 % of the patients showed low or reduced 
HCRP1 expression. Interestingly these patients showed a much more negative 
course of disease compared to patients with regular or high HCRP1 expression. 
These findings fortify our thesis that HCRP1 expression level is correlated with the 
clinical outcome for cancer patients not only in ovarian but also in other kinds of 
cancer. 
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4. Materials and Methods 
4.1. Western Blotting 
4.1.1. Sample Preparation 
Remove media and wash two times with ice cold PBS, add 180µl RIPA+ to a 100mm 
dish. Leave on ice for 5 minutes. Scrape the cells with a cell scraper and transfer the 
lysate to an Eppendorfer tube. Vortex several times (10 seconds each) and leave on 
ice for 5 minutes. Afterwards spin 30 minutes at 12500 rpm at 4°C, save the 
supernatant and discard the pellet. The samples can be stored in RIPA+ up to 6 
month at – 80°C. 
 
4.1.2. RIPA+ buffer 
Reagent MW Stock Store Vol Final 
NaCl 58,44 5M RT 3ml 150mM
Tris pH 7,4 121,14 1M RT 5ml 50mM 
DOC (Na-deoxycholate) 414,6 10% RT (keep dark) 5ml 0,5% 
EGTA 380,4 50mM RT 4ml 2mM 
EDTA pH 7.4 372,2 50mM RT 10ml 5mM 
NaF 41,99 500mM RT 6ml 30mM 
b-Glycerophosphate pH 7,2 216 400mM 4°C 10ml 40mM 
Tetrasodium Pyrophosphate 446,06 100mM RT 10ml 10mM 
Benzamidine 156,6 30mM 4°C 10ml 3mM 
Nonindet P-40  Pure RT 1ml 1% 
 
Set to pH 7,4 and fill with ddH2O to a volume of 95ml. Nonidet P-40 is 
interchangeable with Triton-X-100 
4.1.3. Complete Stock Solution and 2ml RIPA + 
Dissolve one tablette of Complete (stored at 4°C ind the cell culture) in 2ml ddH2O. 
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Take 1,90 ml RIPA, add 20 µl 200mM Na-Orthovanadate and 80 µl 25x Complete 
stock solution. 
4.1.4. Determination of protein concentration (Protein assay) 
In order to determine the concentration o the protein, a Bradford assay was done. 
4.1.5. Gels and Buffers 
According to the size of the protein (41kD) a 12% acrylamide gel was done. 
Acrylamide Concentration (%) Linear Range of Separation (kD)
12 12 – 60 
 
Separating Gel (for 2 gels) 
 
 
 
 
 
 
 
 
Stacking gel (for 2 gels) 
H2O 6,6 ml 
30% acrylamide 8 ml 
1,5 M TRIS (pH=8,8) 8ml 
10% SDS 5ml 
10% APS 200 µl 
TEMED 200 µl 
H2O 5,4 ml 
30% acrylamide 1,34 ml 
1 M TRIS (pH=6,8) 1 ml 
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After pouring the separating gel, add 200-500 µl of Isobutanol to obtain a sharp edge 
at the top of the gel. When the gel is polymerized, discard the Isobutanol and fill in 
the stacking gel and add an appropriate comb. 
 
4.1.6. Sample preparation 
Add DTT to a final concentration of 0,2M to the loading buffer. Dilute the protein 
samples 1:1 with loading buffer and denaturate the samples for 5minutes at 95°C. 
Run the gel at 30V for 15 minutes, then at 160V for approximately 60 minutes. 
 
4.1.7. Blotting 
Cut the membrane and the filter paper to the dimensions of the gel. Soak the filter 
paper and fibre pads in transfer buffer. Activate the PVDF membrane with methanol 
for 10 seconds. Afterwards wash the membrane with ddH2O for 5 min 
Equilibrate the membrane in transfer buffer for 10 min, while shaking it. In the 
meantime prepare the gel-sandwich and blotting apparatus: Place the cassette with 
the grey side down on a clean surface, put one pre-wetted fibre pad on the grey side 
of the cassette.  Two sheets of filter paper are put on the fibre pad, the gel placed on 
the filter paper and the pre-wetted membrane on the gel. Add two more pieces of 
filter papers and finally the last fibre pad. Remove all air bubbles that may have been 
formed. The cassette is placed into the ice cooled module. Run the blot at 300mA for 
one hour. 
10% SDS 80 µl 
10% APS 80 µl 
TEMED 8 µl 
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4.1.8. Blocking, incubation with antibodies and visualization 
The membrane was placed into 100% methanol twice for 10 seconds and washed 
with H2O for 5 minutes. The blocking solution was prepared by diluting western 
blocking reagent 1:10 in PBS/Tween (0,1%). 5 ml of blocking reagent  were added to 
the membrane (proteins facing the inner side) in a 50 ml falcon tube and agitated for 
1 hour at RT. Dilute primary antibody in PBS/Tween complemented with 5% Western 
Blocking Solution. Incubate membrane with primary antibody for 1 hour or at 4°C 
overnight. Wash membrane 3x 5 min in PBS/Tween. Incubate with 2nd antibody 
diluted in PBS/Tween complemented with 5% Western Blocking Solution. Wash 
membrane 3x 5 min in PBS/Tween. Place membrane on a Clingfilm. Mix ECL 
detection reagents 1:1 and apply 3ml for each membrane. Incubate the membrane 
for 1-5 minutes. Transfer membrane onto a new Clingfilm. 
4.2. Used Antibody 
Antibody production - Polyclonal and monoclonal peptide antibodies against 
hVps37A were used for immunohistochemistry experiments and western blotting. 
Tissue microarrays were analyzed using (at that time available) polyclonal antibody, 
whereas immunohistochemistry of mouse tumors and western blotting were 
performed using the monoclonal antibody. The following peptide sequence was 
selected: MSPYASQGFPFLPPY. Rabbit antiserum raised against this peptide 
sequence was prepared and affinity purified by Eurogentec (Seraing, Belgium). 
Rabbit monoclonal antibody was also prepared by Eurogentec. 
 
4.3. Immunostaining  
The slides were placed into Xylene for 10 minutes. For rehydration of the samples 
the slides were put into a series of solutions containing a decreasing amount of 
alcohol (100%; 85%; 70%). Afterwards they were put into AquaDest which was 
changed twice. The slides were put into pH6 Citrate buffer or Epitope Retrieval 
Solution Dako pH9 into a pre warmed water bath for 20 minutes. After cooling, the 
slides were rinsed twice with AD and 5 min with PBS. In order to block the 
endogenous Peroxidase, 3% H2O2 (in PBS) was put on the slides for 10 minutes and 
washed with PBS two times for each 5 minutes. For blocking the samples 10% serum 
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was put on the slides for 10 minutes at room temperature. The first antibody was 
incubated over night at 4°C. Next day 30 min at RT, washing 2-3 times for 5 min and 
incubated with the second antibody. The next day the samples were rinsed twice for 
5 minutes with PBS. In order to amplify the signal an ABC complex was used (1ml 
PBS + 10 µl A + 10 µl B) which was incubated for 45 minutes at RT. The slides were 
rinsed twice for 5 minutes. For signal detection we employed the DAB system which 
through peroxidase activity gives a brownish precipitate. After rinsing again with AD a 
Hematoxylin staining was done on all slides. Thereafter the slides were washed with 
water and dehydrated again with a series of solutions containing an increasing 
amount of alcohol (up to absolute alcohol). Finally the slides were put into n-
Butylacetate. This technique was used for staining of Skov3 and MDAH – 2774 cells, 
as well as staining of the mouse tumour slides. For mouse tumours the slides were 
pre - treated with according to the M.O.M. kit for detecting mouse primary antibody 
on mouse tissue (from Vector laboratories). 
4.4. Immunhistochemistry of the Tissue Micro Array (TMA) 
An arrayed panel of ovarian cancer tissues was prepared. A tissue array was 
assembled by taking core needle “biopsies” from specific locations in the pre-existing 
paraffin-embedded tissue blocks and re-embedding them in an arrayed “master” 
block, using techniques and an apparatus developed by Beecher Instruments, Micro-
Array Technology. To achieve good representation of the tumor, three biopsies of 
tumor material were selected from each patient sample. The ovarian tissue 
microarray was cut into 3 μm thick slices using a microtome. The sections were 
deparaffinized by heating at 60C and rehydrated in descending alcohol grades 
followed by Depp-9 epitope retrieval treatment (EB-depp9-250, eubio, Vienna, 
Austria).  Endogenous peroxidase activity was quenched using 0.2% H2O2 in PBS 
(pH 7.4) for 10 minutes. After blocking with 10% secondary antibody host serum 
(goat) for 45 minutes, the sections were incubated in primary HCRP1 antibody 
[monoclonal EGT290 (1:1000)] for 1 hr at room temperature. Primary antibody 
dilution was made in 10% goat serum. The sections, after 2 PBS washes, were 
incubated in biotinylated secondary antibody [Biotinylated anti-mouse IgG (BA-9200), 
raised in goat; Vector Laboratories, Inc. Burlingame, CA] diluted 1:200 in 10% goat 
serum for 30 minutes at room temperature followed by 45 minute incubation in 
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StreptABComplex/HRP (K0377 Dako, Denmark). The sections were again washed 
twice with PBS and incubated in Dako Liquid DAB+ Substrate Chromogen System 
(K3468 Dako, CA, USA) until the development of brown colour. This was followed by 
counterstaining with Meyer’s hematoxylin, dehydration and mounting using Eukitt 
medium. Staining analysis was performed on Olympus BX50F microscope (Olympus 
Optical Co. Ltd., Japan) using ‘Cell Imaging Software for Life Science Microscopy’ 
(Soft Imaging Solutions GmbH, Münster, Germany). The cells were counted and 
grouped according to percentage of positive cells as <10%, 10-30% and >30% 
positively stained cells. The intensity of staining was determined on a scale of 0 to 3, 
with 0 for absent, 1 for weak, 2 for moderate and 3 for strong staining. The staining 
analysis was performed by three independent investigators. 
4.5. Patient material  
Samples of formaldehyde fixed-paraffin embedded (FFPE) ovarian tumors for 
establishing the tissue microarray (TMA) were obtained from archival material of 144 
patients who underwent radical cytoreductive surgery or between the years 1987 and 
2002 at the Medical University of Vienna, Vienna, Austria. Written and oral informed 
consent was obtained from all patients according to the Ethics Committee of the 
Medical University of Vienna for further processing and analysis of the clinical data. 
The clinical characteristics of patients from the cohort used for the tissue microarray 
are described in Table 1. Microarrays were composed by taking core needle 
“biopsies” from specific locations in the pre-existing paraffin-embedded tissue blocks 
and re-embedding them in an array master block, using techniques and an apparatus 
developed by Beecher Instruments Inc., Micro-Array Technology (Sun Prairie, WI, 
USA). To achieve good representation of the tumor, three biopsies of tumor material 
were selected from each patient. None of the patients with borderline tumors died 
during the follow-up time and were excluded from the survival analysis. No data on 
chemotherapy treatment was available in this cohort, although most patients received 
platinum and taxane based adjuvant regimen according to the institutional standard 
operating procedures. Samples of ovarian tumors for mRNA expression analysis 
were obtained from a second cohort of 115 patients who underwent radical surgery 
the Charité University Hospital, Berlin, Germany between years 2000 and 2004. 
Epithelial-enriched normal ovarian and benign cyst samples came from patients 
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diagnosed without malignant disease at the Medical University of Vienna. In total, 20 
benign ovarian samples and 115 primary tumour samples were assessed. Informed 
consent to sample and data collection by all patients was given according to the 
institutional review board of the Charité University Hospital Berlin and the Medical 
University of Vienna, as stated above. 85 (78.0%) of the patients with ovarian cancer 
in the second cohort underwent chemotherapy with a platinum and taxane based 
regimen. 
 
4.6. Used Antibody 
Antibody production - Polyclonal and monoclonal peptide antibodies against HCRP1 
were used for immunohistochemistry experiments and western blotting. Tissue 
microarrays were analyzed using (at that time available) polyclonal antibody, 
whereas immunohistochemistry of mouse tumors and western blotting were 
performed using the monoclonal antibody. The following peptide sequence was 
selected: MSPYASQGFPFLPPY. Rabbit antiserum raised against this peptide 
sequence was prepared and affinity purified by Eurogentec (Seraing, Belgium). 
Rabbit monoclonal antibody was also prepared by Eurogentec. 
 
4.7. Used cell lines 
For this thesis two ovarian cancer cell lines have been used which have been 
transfected in order to gain stable (MDAH- 2774) and inducible (Skov3) knock down 
of hVps37A protein.  
4.8. shRNA silencing of hVps37A 
 
The human ovarian carcinoma SK-OV-3 cell line was cultured in McCoy´s medium 
enriched with 10% fetal bovine serum (FBS) and cultured in humidified 
incubator (37°C / 5% CO2). For applying the Tet-Off inducible system, founder cell 
lines were generated by transfecting SK-OV-3 cells with the pTet-Off vector (neor) 
encoding a tetracyclin repressible transactivator (tTA). Resistant colonies were 
selected with 200 μg/ml G418 and characterized by transient transfection with the 
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luciferase reporter plasmid (pTRE-Luc) containing luciferase under the control of tTA. 
Cell lines with highest response were used to establish cells inducible for 
hVps37Aspecific shRNA (Open Biosystems; #V2HS_21202, #V2HS_21203), which 
were subcloned into the SIN-TREmiR30-PIG vector (purr) downstream of the 
tetracycline inducible promoter. Presence of tetracycline (doxycycline) in the culture 
medium then suppresses shRNA expression, while its withdrawal would induce the 
knockdown of hVps37A. Puromycin-resistant colonies were isolated in the presence 
of doxycycline, and screened for silencing efficiency of hVps37A by qRT-PCR and 
Western blotting. The human ovarian carcinoma cell line MDAH-2774 was cultured in 
RPMI medium with 10% FCS (fetal calf serum), 50 units/ml penicillin G, and 50 μg/ml 
streptomycin sulfate at 37 °C in a humidified atmosphere of 95% air with 5% CO2. 
Three different shRNA constructs complementary exclusively to the hVps37A mRNA, 
in addition to 1 nonsense construct serving as a control, were cloned into the vector 
pSilencer 4.1-CMV neo. Transfection was performed with Lipofectamine 2000 
according to the manufacturers’ protocol (Invitrogen, Carlsbad, CA, USA). Stable 
clones were selected with 700 μg/ml G418, picked, and sub-cultured with 350 μg/ml 
G418. Silencing efficiency was quantified by qRT-PCR and western blot.  
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Figure 34: Inducible tet - Off HCRP1 knock down system. This system was 
established in Skov3 ovarian cancer cells. These cells were used for the mouse 
xenograft experiment. Upon Dox removal (Dox (-)), shRNA is expressed leading to 
HCRP1 knock down. This leads to abolished EGFR receptor degradation followed by 
receptor recycling and hence cell survival. These tumors showed enhanced growth. 
Dox treatment (Dox (+)) abolishes shRNA expression and HCRP1 knock down. 
Sufficient HCRP1 expression allows EGFR receptor degradation by the ESCRT 
complexes followed by induced apoptosis in tumor cells. These tumors showed 
reduced tumor growth compared to non – Dox treated tumors (PBS treated). 
 
4.9. The Tet- Off System (reviewed in (Nishijima et al., 2009) and Clontech 
protocol) 
 
In biological research the precise regulation of transgene expression is an important 
tool. The tetracycline- regulated gene depletion system (Tet- Off) system is used in 
cultured eucaryotic cells including Drosophila, mice, rats and yeast as well as in 
plants, to control gene activity. The Tet- Off system uses the fact that in E.coli the Tet 
repressor protein (TetR) negatively regulates the genes of the tetracycline resistance 
operon on the Tn 10 transposon. The TetR protein blocks the transcription of these 
genes by binding to the tet operator sequence (tetO) in the absence of Tetracycline 
(Tc). In order to obtain a functional Tet – Off system in a stable cell line, two different 
expression units are needed. The first component is a regulatory protein which is 
based on TetR, which in the Tet – Off system comprises of the fusion of TetR protein 
and the C-terminal activation domain of the Herpes simplex virus VP16. This hybrid 
protein which is called tetracycline controlled transactivator (tTA) in which TetR 
functions as a transcriptional activator. Additionally the plasmid encoding the tTA (the 
pTet – Off regulator plasmid) contains a neomycin resistance gene for selection of 
stably transfected cells. The second component is a Response plasmid which 
expresses a gene of interest (Gene X) which is under control of a tetracycline 
response element (TRE). The TRE is a minimal RNA polymerase II promoter 
sequence (minimal CMV promoter; CMV - Constitutive mammalian promotor) which 
is fused downstream from the multiple Tet resistance operator (TetO) consists of the 
tetO and CMV. Hence in a double stable Tet – Off system cell line Gene expression 
is turnerd on, when Doxicycline (a member of the tetracycline antibiotics group) is 
removed from the media. In our case the controlled Gene of interest (gene X) was a 
HCRP1 specific shRNA in order to obtain an inducible knockdown in transfected 
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Skov3 cells. When Dox was removed from the cell culture media, or in case of the 
xenograft no Dox was injected, HCRP1 specific shRNA was produced which led to 
Gene knock down.  
 
Figure 34: The tet Off system comprises a fusion of the TetR- protein and the 
activator domain of Herpes simplex virus VP16. Both combined are called tTA 
(tetracycline controlled transactivator). The tTa is encoded by the p Tet Off regulator 
plasmid. The response plasmid expresses a gene of interest (Gene X) under control 
of the tetracycline response element (TRE) which consists of the tetO and CMV 
(Constitutive mammalian promoter). Gene expression is turned on, when Dox 
(Tetracycline derivate) is removed from the media. 
 
4.10. Mice xenograft experiment 
 
10 eight week old athymic Foxn1nu mice were maintained under specific 
Pathogen - free conditions. Mice were subcutaneously inoculated with SK-OV-3 
ovarian cancer cells bearing a Dox inducible shRNA construct specific against 
hVps37A (described above). Dox (125μg/day) was intraperitoneal injected in 50% of 
the mice in order to suppress hVps37A knockdown. The remaining mice were treated 
with PBS under the same conditions. Tumor size was measured every third day by 
calliper. Further, the relative tumor growth was calculated as x-fold volume relative to 
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the first measurement. Animal experiments were performed according to protocols 
approved by the Austrian Federal Ministry for Education, Science and Art. 
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4.11. RNA isolation, cDNA synthesis and quantitative RT-PCR 
Total RNA from cell lines was prepared with the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). All steps were accomplished according to the manufacturers' protocols. 
cDNA was synthesized from 1μg total RNA using the DuraScript RT-PCR Kit (Sigma-
Aldrich, Saint Louis, MO, USA) in a volume of 20μl. The following Assay-on-
Demand™ probes were selected for TaqMan real-time PCR: FLJ32642, 
Hs00329751_m1 and beta 2-microglobulin (B2M), Hs99999907_m1, HPRT1 and 
GAPDH (Applied Biosystems, Foster City, CA, USA). The real-time PCR reaction mix 
was composed of 10μl TaqMan® Universal PCR Master Mix (Applied Biosystems) 
supplemented with 2μl of the obtained cDNA, 1μl of the probe and 8μl of ddH2O to a 
total volume of 20μl. The reaction was performed on the 5700 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA) with default cycle conditions. 
Expression was relatively quantified as described elsewhere 35. Briefly, PCR 
efficiencies were calculated from calibration curves for individual probes and 
expression rates were compared with control cells (calibrator). All PCR reactions 
were performed from three independent experiments, and reverse transcriptase-
negative and template-negative controls were included. 
4.12. Data analysis and statistics 
In the tissue microarray analysis, staining intensities were evaluated by two 
independent investigators and classified as 0 (missing expression), 1 (low 
expression), 2 (moderate expression), and 3 (high expression). The tissues were 
graded positive (high or moderate expression) only when more than 10% cells were 
positive for the respective stainings. Patients were dichotomized into two groups at 
the median of hVps37A expression. For EGFR and HER2, results of triplicates and 
both interpretations were averaged and re-scaled (0-3). Staining for HER2, according 
to standard procedures for breast cancer, was divided into two groups with low (0, 1) 
or high (2, 3) expression (Table 2). Since 40% of the tumor samples stained 
negatively or very weakly positively for EGFR, we also dichotomized the samples into 
two groups of low and high EGFR expression (Table 2). Kaplan-Meier plots and 
overall survival analysis were calculated with a median follow-up of 40.0 months 
(range 0.4–168.7 months) and event rate of 30.4%. Groups were compared using the 
log-rank test. Only patients with available staining for EGFR, HER2 and hVps37A 
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were included in the survival analysis. Logistic regression (ROC curves) was used to 
calculate specificity and sensitivity for the 5-year survival prognosis of EGFR and 
HER2. Nonparametric correlations between expression levels and categorical clinical 
variables were calculated using Spearman’s rho test. 
In the mRNA expression analysis we used relative normalized expression values for 
hVps37A expression of the normal (N) and ovarian patient (PT) cohort as measured 
by qRT-PCR. Group means were compared using Student’s t-test. All statistical 
analyses were performed using the SPSS statistical software (Chicago, IL, USA). 
 
4.13. Fluorescence microscopy and TUNEL assay 
 
Cells were seeded on chamber slides, grown for 48 hours, fixed with 4% 
paraformaldehyde for 15 minutes, and permeabilized with 0.1% Triton X-100. The 
subsequent staining procedure was performed as described for immuno- 
histochemistry. The cells were incubated with the primary antibodies directed against 
pEGFR or EEA1 (1:100) for 1 hour. Alexa 610/350 secondary antibodies (1:100) 
were applied for 45 minutes. Afterwards the cells were analyzed on a confocal 
microscope. The “In Situ Cell Death Detection Kit, Fluorescin” (TUNNEL Assay) was 
obtained from Roche (Mannheim, Germany) and conducted according to the 
manufacturers protocol. DNaseI-treated samples served as positive controls. 
 
4.14. Proliferation assays 
 
2x105 SK-OV-3 (with and without doxycyclin) and MDAH (hVps37A silenced, 
nonsense control and wildtype) cells were seeded in 6-well plates in media 
complemented with 10% FCS and treated with 20 μg/ml cetuximab (Merck, 
Whitehouse Station, NJ, USA), 4 μM lapatinib (GlaxoSmithKline plc. London, UK), or 
were mock-treated. To maintain the logarithmic phase, cells were split at intervals of 
48 hours, along with the determination of the cell number by a CASY cell counter 
(Innovatis AG, Bielefeld, Germany). This procedure was performed in triplicate over a 
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time-span of 6 days and confirmed by a replication of the whole experiment. From the 
obtained data, doubling times (dt) were calculated and depicted as dt-1. 
 
4.15. 3D cell culture experiments 
 
SK-OV-3 ovarian cancer cells bearing a Dox inducible shRNA construct specific 
against hVps37A (described above) were induced to form multicellular spheroids in 
non-adhesive 96-well plates in the presence (control) or absence (knockdown) of Dox 
and grown for 72 hours. The spheroids were transferred to collagen gels (rat 
Collagen 1, Becton Dickinson, 1.75mg/ml Collagen) and incubated in FGM 
supplemented with 2.5% serum (+/- Dox) and grown for further 72 hours. Spheroids 
were photographed and the areas of invasive structures were determined with the 
Axiovision software (Zeiss). 
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2 
Statement of Translational Relevance. Our study shows that hVps37A is 
downregulated in a large number of ovarian cancer tissues and influences prognostic 
relevance of EGFR and HER2 expression. Moreover, we find that loss of hVps37A 
leads to cetuximab resistance in vitro. We propose that hVps37A expression might 
be exploitable as a prognostic and predictive marker in ovarian cancer and possibly 
in other cancer entities as well. 
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Purpose: Although prognostic and predictive factors in ovarian cancer have 
been extensively studied for decades, only few have been identified and introduced 
to clinical practice. Here we evaluate hVps37A (HCRP1) as a possible novel 
predictive marker for ovarian cancer. hVps37A was originally described as a member 
of the membrane-trafficking ESCRT-I complex mediating the internalization and 
degradation of ubiquitinated membrane receptors.  
Experimental Design: We analyzed a ovarian cancer tissue microarray for 
HCRP1, EGFR and HER2 expression. We used a tetracycline inducible ovarian 
cancer cell culture model to demonstrate the effects of hVps37A knockdown in vitro 
and in vivo. Additionally, we studied the effects of EGFR inhibitors cetuximab and 
lapatinib on ovarian cancer cells under conditions of hVps37A knockdown. 
Results: We find that hVps37A is significantly downregulated in ovarian 
cancer and modifies the prognostic value of EGFR and HER2 expression. 
Additionally, hVps37A down-regulation in ovarian cancer cells leads to cytoplasmic 
pEGFR retention and hyperactivation of downstream pathways and is associated 
with enhanced xenograft growth in nude mice as well as invasion of the collagen 
matrix. Furthermore, due to subsequent sustained Akt- and MAPK-pathway 
activation, hVps37A-deficient cells become irresponsive to inhibition by the 
therapeutic antibody cetuximab. 
Conclusions: We propose that hVps37A status could become a novel 
prognostic and therapeutic marker for EGFR or HER2 driven tumors. 
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Introduction 
Reliable prediction of prognosis and therapeutic response based on molecular 
factors will undoubtedly lead to more personalized cancer medicine. Despite 
increasing biological knowledge though, only few biological markers for ovarian 
cancer have entered clinical practice so far. The ErbB family comprises four 
members (ERBB1-4), of which ERBB1 (EGFR) is the most prominent. EGFR is a 
170 kDa transmembrane RTK that plays an essential role in governing multiple 
cellular processes, including cell proliferation, survival, and cell migration (1, 2). 
Targeting of epidermal growth factor receptor (EGFR) and other ErbB family 
members as well as their downstream pathways is a mainstay of treatment in many 
malignant diseases. Activation by EGF or EGF-like ligands leads to receptor 
dimerization and autophosphorylation of cytoplasmic residues (3). The phospho-
tyrosine residue itself serves as a docking platform for several adaptor molecules, 
triggering the activation of various pathways including the RAS-RAF-MEK-ERK 
pathway, the PI3K-Akt pathway, and the PLC-gamma-PKC pathway (4). 
Hyperactivation of EGFR-dependent signal transduction often accompanies tumor 
development, and cancer patients with unbalanced EGFR activity generally present 
with a more aggressive disease leading to unfavorable clinical outcome (5). It is 
widely believed that hyperactivation of EGFR-mediated signal transduction can be 
triggered by a) increased ligand expression, b) elevated EGFR protein expression, c) 
activating EGFR mutations, d) defective EGFR down-regulation, and e) cross-talk 
with heterologous receptor systems (6). Introduction of the anti-EGFR antibody 
cetuximab (IMC-C225, Erbitux) to clinical practice represented a major breakthrough 
in cancer therapy. Cetuximab binding leads to inhibition of EGFR dependent 
signaling pathways, activation of antibody dependent cellular cytotoxicity (ADCC) and 
consequently to apopotosis and decreased cellular proliferation, survival and 
migration (1, 2). Cetuximab is a chimeric monoclonal antibody binding extracellular 
domain of EGFR, preventing receptor dimerization and activation as well as 
triggering its internalization and degradation (3). 
EGFR down-regulation by the endosomal sorting process depends on 
receptor internalization via endocytosis, as well as subsequent vesicular shuttling 
towards one of three distinct cytoplasmic compartments (7). The internalized receptor 
can (1) be directed back to the cell surface, (2) enter the trans-Golgi network (TNG), 
or (3) be transported into the intraluminal vesicles (ILVs) forming multivesicular 
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bodies (MVBs), which are subsequently degraded upon fusion with the lysosome (8, 
9). The endosomal sorting complex required for transport-I (ESCRT-I) is one of three 
protein complexes essential for sorting of ubiquitinated transmembrane proteins into 
internal vesicles of MVBs and subsequent degradation. Vps37A (vacuolar protein 
sorting 37 homolog A) was initially described in yeast as one of the three subunits of 
ESCRT-I (10).  
The human homologue of Vps37A (hVps37A), is located on the short arm of 
chromosome 8. For this region, 8p22 loss of heterozygosity (LOH) occurs to a high 
frequency in several human cancers including ovarian cancer. The expression of 
hVps37A was found to be reduced or undetectable in hepatocellular carcinoma 
(HCC) (11) by a positional cloning approach and consequently the name HCRP1 
(hepatocellular carcinoma related protein) was suggested. First functional data 
showed that overexpression in the HCC cell line SMMC-7721 significantly inhibited 
cell growth in vitro, whereas siRNA mediated knockdown of HCRP1 in the HCC cell 
line BEL-7404 resulted in increased cellular proliferation (11). In a more detailed 
study, hVps37A was shown to interact with Tsg101 and hVps28 via its mod(r) domain 
and depletion of hVps37A in HeLa cells diminished EGFR degradation (12). 
Nonetheless, hVps37A has been poorly characterized so far. Since hVps37A was 
reported to be involved in the EGFR degradation process and regulating cellular 
proliferation, we suspected that it might be also involved in ovarian cancer 
pathogenesis. We set out to characterize the function of hVps37A in an ovarian 
cancer model in-vitro and in-vivo as well as define its influence on prognosis of 
ovarian cancer patients. 
 
Materials and Methods 
Patient material  
Samples of formaldehyde fixed-paraffin embedded (FFPE) ovarian tumors for 
establishing the tissue microarray (TMA) were obtained from archival material of 144 
patients who underwent radical cytoreductive surgery or between the years 1987 and 
2002 at the Medical University of Vienna, Vienna, Austria. Written and oral informed 
consent was obtained from all patients according to the Ethics Committee of the 
Medical University of Vienna for further processing and analysis of the clinical data. 
The clinical characteristics of patients from the cohort used for the tissue microarray 
are described in Table 1. Microarrays were composed by taking core needle 
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“biopsies” from specific locations in the pre-existing paraffin-embedded tissue blocks 
and re-embedding them in an array master block, using techniques and an apparatus 
developed by Beecher Instruments Inc., Micro-Array Technology (Sun Prairie, WI, 
USA). To achieve good representation of the tumor, three biopsies of tumor material 
were selected from each patient. None of the patients with borderline tumors died 
during the follow-up time and were excluded from the survival analysis. No data on 
chemotherapy treatment was available in this cohort, although most patients received 
platinum and taxane based adjuvant regimen according to the institutional standard 
operating procedures. 
Samples of ovarian tumors for mRNA expression analysis were obtained from 
a second cohort of 115 patients who underwent radical surgery the Charité University 
Hospital, Berlin, Germany between years 2000 and 2004. Epithelial-enriched normal 
ovarian and benign cyst samples came from patients diagnosed without malignant 
disease at the Medical University of Vienna. In total, 20 benign ovarian samples and 
115 primary tumor samples were assessed. Informed consent to sample and data 
collection by all patients was given according to the institutional review board of the 
Charité University Hospital Berlin and the Medical University of Vienna, as stated 
above. The clinical characteristics of these patients are described in Table 1. 85 
(78.0%) of the patients with ovarian cancer in the second cohort underwent 
chemotherapy with a platinum and taxane based regimen. 
 
RNA isolation, cDNA synthesis and quantitative RT-PCR 
Total RNA from cell lines was prepared with the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and quality and quantity assessed on RNA Nano Chips (Lab-on-a-
Chip, Agilent Technologies, Palo Alto, CA, USA). All steps were accomplished 
according to the manufacturers' protocols.  
cDNA was synthesized from 1µg total RNA using the DuraScript RT-PCR Kit 
(Sigma-Aldrich, Saint Louis, MO, USA) in a volume of 20µl and subsequently diluted 
to a total volume of 100µl. The following Assay-on-Demand™ probes were selected 
for TaqMan real-time PCR: FLJ32642, Hs00329751_m1 and beta 2-microglobulin 
(B2M), Hs99999907_m1, HPRT1 and GAPDH (Applied Biosystems, Foster City, CA, 
USA). The real-time PCR reaction mix was composed of 10µl TaqMan® Universal 
PCR Master Mix (Applied Biosystems) supplemented with 2µl of the obtained cDNA, 
1µl of the probe and 8µl of ddH2O to a total volume of 20µl. The reaction was 
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performed on the 5700 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA) with default cycle conditions. Expression was relatively quantified as 
described elsewhere (13) and its log-transformed values were used in the analysis. 
Briefly, PCR efficiencies were calculated from calibration curves for individual probes 
and expression rates were compared with control cells (calibrator). All PCR reactions 
were performed from three independent experiments, and reverse transcriptase-
negative and template-negative controls were included. 
 
Cell culture and shRNA silencing of hVps37A 
The human ovarian carcinoma SK-OV-3 cell line was cultured in McCoy´s 
medium enriched with 10% fetal bovine serum (FBS) and cultured in humidified 
incubator (37°C / 5% CO2). For applying the Tet-Off inducible system, founder cell 
lines were generated by transfecting SK-OV-3 cells with the pTet-Off vector (neor) 
encoding a tetracyclin repressible transactivator (tTA). Resistant colonies were 
selected with 200 µg/ml G418 and characterized by transient transfection with the 
luciferase reporter plasmid (pTRE-Luc) containing luciferase under the control of tTA. 
Cell lines with highest response were used to establish cells inducible for hVps37A-
specific shRNA (Open Biosystems; #V2HS_21202, #V2HS_21203), which were 
subcloned into the SIN-TREmiR30-PIG vector (purr) downstream of the tetracycline 
inducible promoter. Presence of tetracycline (doxycycline, Dox) in the culture medium 
then suppresses shRNA expression, while its withdrawal would induce the 
knockdown of hVps37A. Puromycin-resistant colonies were isolated in the presence 
of doxycycline, and screened for silencing efficiency of hVps37A by qRT-PCR and 
Western blotting. 
The human ovarian carcinoma cell line MDAH-2774 was cultured in RPMI 
medium with 10% FCS (fetal calf serum), 50 units/ml penicillin G, and 50 μg/ml 
streptomycin sulfate at 37 °C in a humidified atmosphere of 95% air with 5% CO2. 
Three different shRNA constructs complementary exclusively to the hVps37A mRNA 
in addition to one nonsense construct serving as a control, were cloned into the 
vector pSilencer 4.1-CMV neo. Transfection was performed with Lipofectamine 2000 
according to the manufacturers’ protocol (Invitrogen, Carlsbad, CA, USA). Stable 
clones were selected with 700 µg/ml G418, picked, and sub-cultured with 350 µg/ml 
G418. Silencing efficiency was quantified by qRT-PCR and western blot.  
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Antibody production 
Polyclonal and monoclonal peptide antibodies against hVps37A were used for 
immunohistochemistry experiments and western blotting. Tissue microarrays were 
analyzed using (at that time available) polyclonal antibody, whereas 
immunohistochemistry of mouse tumors and western blotting were performed using 
the monoclonal antibody. The following peptide sequence was selected: 
MSPYASQGFPFLPPY. Rabbit antiserum raised against this peptide sequence was 
prepared and affinity purified by Eurogentec (Seraing, Belgium). Rabbit monoclonal 
antibody was also prepared by Eurogentec. 
 
Immunohistochemistry  
After deparaffinization and rehydration, the samples were treated with 0.3% 
H2O2/PBS (pH 7.4) for 10 minutes to quench endogenous peroxidase activity and 
blocked with serum of the secondary antibody diluted 1:50 in PBS. Primary 
antibodies against EGFR (EGFR (1005) Santa Cruz Biotechnology, Inc., CA, USA) 
and hVps37A were diluted 1:100 in serum/PBS and applied on the samples for 1 
hour. HER2 was stained using the Dako HercepTest™ (Dako, Glostrup, Denmark). 
The secondary anti-rabbit antibody was applied for 30 minutes. For Ki-67 stainings, 
epitope retrieval was done using Depp-9; endogenous peroxidase activity was 
quenched using 0.3% H2O2 in Methanol. The dilution for both the primary monoclonal 
mouse, anti-human Ki-67 (M7240, Dako, Glostrup, Denmark) and secondary anti-
mouse antibody (Vector Laboratories) was 1:200. After visualization with DAB+ 
(Dako, CA, USA) and counterstaining with hematoxyline/eosin, the slides were 
mounted in Eukitt (O. Kindler GmbH, Freiburg, Germany) and analyzed on an 
Olympus BX50 upright light microscope (Olympus Europe, Hamburg, Germany) 
equipped with the Soft Imaging system CC12. 
The tissue microarrays were treated in an identical manner and the entire 
cohort was analyzed in one batch containing three slides per staining. Reagent 
conditions, incubation times and temperatures, and antigen retrieval (if necessary) 
were performed as previously described.  
 
Data analysis and statistics 
In the tissue microarray analysis, staining intensities were evaluated by two 
independent investigators and classified as 0 (missing expression), 1 (low 
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expression), 2 (moderate expression), and 3 (high expression). The tissues were 
graded positive (high or moderate expression) only when more than 10% cells were 
positive for the respective staining. For EGFR and HER2, results of triplicates and 
both interpretations were averaged and re-scaled (0-3). Staining for HER2, according 
to standard procedures for breast cancer, was divided into two groups with low (0, 1) 
or high (2, 3) expression (Table 2). Patients were dichotomized into two groups at the 
median of hVps37A expression. Since 40% of the tumor samples stained negatively 
or very weakly positively for EGFR, we also dichotomized the samples into two 
groups of low and high EGFR expression (Table 2). Overall survival analysis was 
performed with a median follow-up of 40.0 months (range 0.4–168.7 months) and 
event rate of 30.4%. Kaplan-Meier estimates of overall survival were obtained and 
groups were compared using the log-rank test. Only patients with available staining 
for EGFR, HER2 and hVps37A were included in the survival analysis. Logistic 
regression (ROC curves) was used to calculate specificity and sensitivity for the 5-
year survival prognosis of EGFR and HER2. Nonparametric correlations between 
expression levels and ordinal or binary clinical variables were calculated using 
Spearman’s rho. 
In-vivo xenograft experiments were analyzed using unpaired Student’s t-test. 
The mRNA expression analysis used relative normalized expression values for 
hVps37A expression of the normal (N) and ovarian patient (PT) cohort as measured 
by qRT-PCR. Group means were compared using Student’s t-test. All statistical 
analyses were performed using the SPSS statistical software (Chicago, IL, USA). 
 
Protein isolation and western blotting 
The following antibodies were used in the dilution indicated: hVps37A 1:200 
(established as described above); primary antibodies ( EGFR 1:300, pEGFR 1:100, 
HER2 1:200, pHER2 1:200, ERK1 1:5000, ERK2 1:5000 and beta-actin 1:300) and 
HRP-conjugated secondary antibodies (anti-goat 1:10000 and anti-rabbit 1:10000) 
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) Akt and 
pAkt were purchased from Cell Signaling Technology (Beverly, MA, USA). Upon 
treatment, cells were lysed and protein was prepared with RIPA+ buffer; protein 
concentration was determined by a standard Bradford absorbance assay (Sigmal 
Aldrich, Saint Louis, MO, USA). Equal amounts of proteins (30µg) were separated by 
SDS-PAGE, blotted on PVDF membranes (GE Healthcare, Buckinghamshire, UK), 
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incubated with the appropriate primary antibody, and visualized via HRP-conjugated 
secondary antibodies and treatment with the ECL chemiluminescent detection 
system (GE Healthcare, Buckinghamshire, UK). 
 
Fluorescence microscopy and TUNEL assay 
Cells were seeded on chamber slides, grown for 48 hours, fixed with 4% 
paraformaldehyde for 15 minutes, and permeabilized with 0.1% Triton X-100. The 
subsequent staining procedure was performed as described for immuno-
histochemistry. The cells were incubated with the primary antibodies directed against 
pEGFR or EEA1 (1:100) for 1 hour. Alexa 610/350 secondary antibodies (1:100) 
were applied for 45 minutes. Afterwards the cells were analyzed on a confocal 
microscope.  
The “In Situ Cell Death Detection Kit, Fluorescin” (TUNNEL Assay) was 
obtained from Roche (Mannheim, Germany) and conducted according to the 
manufacturers protocol. DNaseI-treated samples served as positive controls. 
 
Proliferation assays  
2x105 SK-OV-3 (with and without doxycycline, Dox) and MDAH (hVps37A 
silenced, nonsense control and wildtype) cells were seeded in 6-well plates in media 
complemented with 10% FCS and treated with 20 µg/ml cetuximab (Merck, 
Whitehouse Station, NJ, USA), 4 µM lapatinib (GlaxoSmithKline plc. London, UK), or 
were mock-treated. To maintain the logarithmic phase, cells were split at intervals of 
48 hours, along with the determination of the cell number by a CASY cell counter 
(Innovatis AG, Bielefeld, Germany). This procedure was performed in triplicate over a 
time-span of 6 days and confirmed by a replication of the whole experiment. From the 
obtained data, doubling times (dt) were calculated and depicted as dt-1. 
 
3D cell culture experiments 
SK-OV-3 ovarian cancer cells bearing a Dox inducible shRNA construct 
specific against hVps37A (described above) were induced to form multicellular 
spheroids in non-adhesive 96-well plates in the presence (control) or absence 
(knockdown) of Dox and grown for 72 hours. The spheroids were transferred to 
collagen gels (rat Collagen 1, Becton Dickinson, 1.75mg/ml Collagen) and incubated 
in FGM supplemented with 2.5% serum (+/- Dox) and grown for further 72 hours. 
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Spheroids were photographed and the areas of invasive structures were determined 
with the Axiovision software (Zeiss).  
 
Mice xenograft experiments 
Each treatment group consisted of 10 eight week old athymic Foxn1nu mice, 
which were maintained under specific pathogen-free conditions at the Institute for 
Cancer Research of the Medical University of Vienna. All mice were subcutaneously 
inoculated with SK-OV-3 ovarian cancer cells bearing a doxycycline inducible shRNA 
construct specific against hVps37A (described above). Dox (125µg/day) was injected 
intraperitoneally in 50% of the mice in order to suppress hVps37A knockdown. The 
remaining mice were treated with PBS under the same conditions. Tumor size was 
measured every third day in two axes using a calliper. Tumor volume was calculated 
using the formula: volume = ½(length x width2). Animal experiments were performed 
according to protocols approved by the Austrian Federal Ministry for Education, 
Science and Art. 
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Results 
Prognostic Value of EGFR and HER2 is Dependent on hVps37A Status 
 Since hVps37A was suggested to be involved in endosomal RTK-degradation 
(12), we thought that it might potentially influence the impact of EGFR/HER2 
expression on the survival of ovarian cancer patients. Thus, we undertook a tissue 
microarray (TMA) analysis to test this hypothesis. Median follow-up for patients with 
malignant ovarian tumors was 40.0 months (range 0.4–168.7 months), and 38 
patients (30.4%) had already died. The TMAs were analyzed for protein expression 
of EGFR and HER2, as these receptors represent well studied markers for ovarian 
carcinogenesis and progression and are also targets of hVps37A-mediated receptor 
degradation. The representative staining intensities for hVps37A, EGFR and HER2 in 
the ovarian TMA are shown in Figure 1. Not surprisingly, high protein expression of 
the oncogenes EGFR (p=0.005) as well as HER2 (p=0.002) was associated with 
unfavorable overall survival rates, thus confirming our previous results and those of 
others (14) (Fig. 2A, D). Further, we looked at hVps37A expression in the same 
tumor samples. Consistent with the notion that hVps37A is involved in the endosomal 
sorting process of RTKs, it was primarily detected in the cytoplasm (Fig. 1). hVps37A 
expression was graded according to staining intensity (Fig. 1) and the patient cohort 
was divided at the median into two subgroups according to hVps37A expression. We 
observed a relatively high percentage (62%) of tumors with low or missing hVps37A 
expression in this patient population (Table 2), though hVps37A expression alone did 
not have an impact on overall survival of ovarian cancer patients (Fig. 2G). No 
significant differences regarding FIGO stage, grade or histological subtype were 
observed between high and low hVps37A expressing patients (Table 2). There was a 
weak, but significant positive correlation between EGFR and hVps37A expression 
(Spearman’s rho=0.348, p<0.001). 
To further identify and confirm the loss of hVps37A in ovarian cancer, we 
analyzed an independent cohort of ovarian cancer patients and measured hVps37A 
expression at the mRNA level. In this cohort, we also found hVps37A mRNA 
downregulation in ovarian cancer when compared to normal (epithelialy enriched) 
ovarian tissue (Fig. 3A), again indicating a deficiency of hVps37A expression in 
ovarian cancer. Further survival analysis of this cohort was not possible due to the 
short follow-up period. 
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To evaluate the impact of hVps37A expression on the prognostic impact 
EGFR and HER2, we stratified overall survival of our patients based on hVps37A 
expression. Interestingly, we can observe the strong impact of HER2 (p<0.001) as 
well as EGFR (p=0.003) expression on overall survival only in tumors with low or 
missing hVps37A protein expression (Fig. 2C, F). This well known prognostic 
influence of HER2 and EGFR is largely lost in cases with regular (high) hVps37A 
expression (Fig. 2B, E). Logistic regression (ROC curves) was used to calculate 
specificity and sensitivity for the 5-year survival prognosis of EGFR and HER2 
(Supplementary Fig. 1A-D). In line with corresponding Kaplan-Meier curves, we 
observe that the prognostic specificity and sensitivity of EGFR and HER2 is 
dependent on hVps37A expression, as reflected by the area under the curve (AUC). 
This observation points towards a possible influence of the receptor degradation 
mechanism on clinical relevance of growth factor receptor expression. Consequently, 
EGFR or HER2 overexpression may have an impact on patients’ prognosis only in 
tumors with decreased hVps37A expression. 
 
Activated EGFR and HER2 Accumulate in hVps37A-Negative Cell Lines 
We used ovarian cancer cell lines to gain closer insights into the causal 
biological mechanisms behind our findings. SK-OV-3 and MDAH-2774 ovarian 
cancer cell lines, which have detectable expression of EGFR and HER2, were 
established as model system for functional studies. hVps37A mRNA SK-OV-3 and 
MDAH-2774 was stably knocked down via a doxycycline inducible shRNA (SK-OV-3) 
or constitutive approach (MDAH-2774), respectively, and silencing efficiencies were 
determined on mRNA and protein levels (Fig. 3B, C, Supplementary Fig. 2A, B). We 
obtained clones with 60-70% reduction of hVps37A mRNA/protein, leading to 
elevated levels of activated EGFR and HER2 in the SK-OV-3 and MDAH-2774 cell 
lines. We juxtaposed hVps37A expression with activated EGFR receptor levels and 
found elevated phosphorylated EGFR while EGFR levels remained constant (Fig. 3B, 
Supplementary Fig. 2B). This resulted in a significant increase of the pEGFR/EGFR 
ratio. These observations suggest that activated EGFR accumulates within 
hVps37A–deficient cells as a result of defects in receptor degradation. We further 
aimed to define the cellular compartment harboring the aberrantly retained pEGFR 
protein using immunofluorescence. In control cells, pEGFR was hardly detectable 
(Fig. 3C). In contrast, pEGFR was detected at much higher levels in the cytoplasm of 
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hVps37A knockdown cells. Frequent co-localization with the early endosomal marker 
EEA1 (Fig. 3C) indicated that pEGFR may accumulate primarily in sorting 
endosomes. This observation further supports the notion of ineffective receptor 
sorting in hVps37A depleted cells. To see if this concept can be extended to other 
cell lines of ovarian and mammary origin, we quantified hVps37A, (p)EGFR and 
(p)HER2 by immunoblot analysis in 15 ovarian and breast cancer cell lines and 
plotted the ratios of activated to total receptor versus hVps37A (Fig. 4B). No 
significant association between hVps37A and EGFR (r = 0.111; p=0.695) was found, 
yet we observed a significant (p<0.01) reciprocal correlation between hVps37A and 
pEGFR protein expression (r = -0.683; p=0.007) as well as between hVps37A and 
pEGF/EGFR protein ratio (r = -0.719; p=0.005). A statistically weak correlation was 
also found between hVps37A and pHER2 protein expression, but did not reach the 
level of significance (data not shown). All these observations lead us to the 
conclusion that phosphorylated EGFR receptor accumulation in ovarian cancer may 
be caused by defects in endosomal protein degradation. To further validate this 
hypothesis, we studied the dynamics of pEGFR degradation in wild-type and 
hVps37A knockdown cells. After incubation in a serum-free medium, cells were 
stimulated with 100ng/ml EGF for 15 minutes to achieve receptor activation followed 
by re-incubation in serum-free medium. At defined time points, cells were harvested 
and pEGFR expression determined by Western blotting. pEGFR degradation was 
significantly impaired in hVps37A deficient cells while total receptor levels remained 
constant in SK-OV-3 and MDAH-2774 cell lines (Fig. 4A, Supplementary Fig. 2C), 
suggesting sustained EGFR signaling in these cells. This led us to investigate the 
effects of hVps37A upon treatment with EGFR inhibiting agents. 
 
hVps37A Interferes with EGFR Signal Transduction and Anti-EGFR Antibody 
Treatment  
 Characterizing changes in EGFR-downstream signalling upon hVps37A 
knockdown might shed further light on the role of hVps37A in ovarian carcinogenesis. 
We therefore analyzed differences in ErbB-signalling pathways in hVps37A 
knockdown versus control cells. Consistent with extensive receptor phosphorylation 
and downstream pathway activation, knockdown of hVps37A was associated with 
increased phosphorylation of Erk1/2 (Fig. 4C, Supplementary Fig. 2D). Unlike Erk, 
Akt phosphorylation at serine 473 was not changed in the two cell lines studied, 
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arguing for baseline Akt phosphorylation not being affected by sustained growth 
factor signalling upon hVps37A knockdown in ovarian cancer cells. Next, we 
wondered if EGFR inhibition by anti-EGFR antibody cetuximab or EGFR/HER2 
tyrosine kinase inhibitor lapatinib might have any consequences on EGFR 
phosphorylation in hVps37A knockdown cells. Lapatinib treatment did inhibit EGFR 
downstream signalling in both, hVps37A knockdown and wildtype cells, as evidenced 
by dephosphorylation of Erk1/2 and Akt in the SK-OV-3 and MDAH-2774 cell lines 
(Fig. 4C, Supplementary Fig. 2D).  Interestingly, this was not the case for cetuximab. 
After cetuximab treatment, Erk1/2 and Akt remained phosphorylated in hVps37A 
knockdown cells. Cytoplasmic degradation of phosphorylated EGFR seems to be 
crucial for cetuximab-dependent inhibition of its downstream pathways. On the other 
hand, EGFR inhibition by lapatinib is rather mediated by its direct interaction with the 
tyrosine kinase domain, independent of endosomal processing and consequently 
unaffected by hVps37A status. 
Dysfunctional activation of Erk-signal transduction leads to increased cellular 
proliferation, invasion and tumorigenesis. We studied the proliferation of control cells 
and hVps37A knockdown SK-OV-3 cells, which reveals comparable rates (25.5 
versus 24.9 hours doubling time, respectively), thus indicating a limited impact of 
hVps37A on cellular proliferation under unstressed, untreated in-vitro conditions (data 
not shown). Incubation with cetuximab, however, significantly decreases the 
proliferation potential of the control cells expressing hVps37A (p<0.01), whereas the 
respective hVps37A knockdown cells remain unaffected. This fact indicates that the 
presence of hVps37A is essential for proper degradation of the receptor-antibody 
complex, which has been shown to be essential for efficient cetuximab mediated anti-
tumor activity (15). EGFR/HER2 inhibition by lapatinib significantly reduced cell 
proliferation irrespective of hVps37A expression levels (p<0.01) in SK-OV-3 and 
MDAH-2774 cell lines (Fig. 4D, Supplementary Fig. 2E).  
 
Loss of hVps37A Drives Invasive Potential of Cancer Cells 
In order to simulate physiological tumor growth conditions, we allowed SK-OV-
3 cells to grow in 3D collagen cultures. In detail, we seeded the cells into non-
adhesive 96-well plates containing methylcellulose complemented media to generate 
tumor-like spheroids of several hundred cells. The spheroids were subsequently 
transferred to collagen gels and incubated for 72 hours. Overall growth rate of the 
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spheroids was not affected by hVps37A expression (data not shown). However, 
hVps37A-knockdown cells gained the ability to invade the collagen matrix more 
efficiently (Fig. 5A, B). The invasive potential was calculated as percentage area of 
outgrowing cells relative to the central area of the spheroid, resulting in a mean of 
73.5% for the hVps37A knockdown cells compared to 30% for the controls (t-test p < 
0.001). These data suggest that hVps37A affects in-vitro invasive characteristics of 
the cells rather than their proliferation.  
 
Enhanced Growth of hVps37A Knockdown Cells in Mouse Xenografts 
Next, we were curious about the in-vivo growth characteristics of the Vps37A-
knockdown SK-OV-3 cells in a mouse xenograft model. 5x106 cells were 
subcutaneously inoculated into hind flanks of nude mice, half of which were treated 
with doxycycline in order to obtain suppression of the shRNA construct. The mice 
were sacrificed according to the institutional ethics committee protocols. Tumor 
growth was increased in mice with hVps37A-knockdown xenografts, resulting in final 
mean tumor volumes of 1027mm3 compared to 683mm3 for the un-induced tumors 
(p<0.001, Fig. 5C). The tumors were paraffin-embedded for subsequent analysis and 
successful knockdown of hVps37A was confirmed via IHC staining (Fig. 5D). 
Interestingly, cellular proliferation was not significantly affected as determined by a 
Ki67 assay (Fig. 5F). However, we observed significantly decreased apoptosis rates 
for the Vps37A-knockdown tumors (Fig. 5E). These data indicate that the tumor 
growth effect can be traced back to sustained survival rather than elevated 
proliferation. 
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Discussion 
Activation of ErbB RTK family isoforms is often associated with tumor 
development and progression. One of the mechanisms leading to hyperactivation of 
ErbB receptor signalling is defective receptor degradation. Recently, hVps37A has 
been recognized as a member of the ESCRT-I complex. While we could not detect 
mutations in the coding region of hVps37A (unpublished results), we observed 
hVps37A mRNA and protein expression to be significantly reduced in primary ovarian 
cancer, indicative for a negative selection pressure against hVps37A expression.  
Due to the cytosolic orientation of the phosphorylated tail of RTKs, receptors 
targeted for endosomal degradation are still signaling competently, an effect which is 
probably increased by the observed cytoplasmic retention of pEGFR (16). In fact, we 
describe an increase in Erk1/2 phosphorylation upon knockdown of hVps37A, while 
basal phosphorylation of Akt remains unchanged. A possible explanation for this 
effect may be that endosomally located phosphorylated EGFR can not activate PI3K 
signaling (17), while other signaling pathways remain unaffected. MAPK activation 
leads to different responses dependent on the cellular background or intensity and 
duration of the signal (18-21). 
Our findings resemble closely those established for Tsg101, another 
component of the ESCRT-I protein complex. It has been reported that the endosomal 
degradation of EGFR is impaired in Tsg101-deficient cells (22). In addition, non-
functional Tsg101 causes EGFR accumulation within the cytoplasm (23). However, 
the function of Tsg101 as a tumor suppressor gene is controversial, since its knock-
out did not result in cellular transformation and increased proliferation in mouse 
embryonic fibroblasts (24). Our results argue in favor of the occurrence of non-
functional ESCRT-I complexes under conditions of hVps37A knockdown. We assume 
that in contrast to Tsg101, hVps37A might indeed constitute a novel tumor 
suppressor in ovarian cancer, as this function is assumed for the functional ESCRT-I 
complex (24). 
EGFR is overexpressed in about 60% of ovarian epithelial cancers and its 
activation is correlated with increased tumor growth and invasion as well as poor 
patient outcome (25, 26). We found that hVps37A significantly affects the prognostic 
impact of EGFR and HER2 expression in ovarian cancer (14, 27). Under conditions 
of low hVps37A expression, both EGFR and HER2 expression levels were highly 
prognostic, a trait which was completely abrogated under conditions of high hVps37A 
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expression. Obviously, hVps37a deficiency tips the fine balance between RTK 
activation and subsequent degradation, furthermore influencing patients' survival. 
Multiple marker testing would thus be beneficial to obtain a more reliable and 
accurate picture of the disease. If our results can be confirmed in more 
comprehensive clinical studies, hVps37A-testing could define a novel path in EGFR - 
and HER2 testing of ovarian cancer.  
The clinical use of several EGFR targeted therapies in ovarian cancer has 
been limited due to their low efficacy in phase I and II trials (26, 28). EGFR is at the 
same time a putative target for hVps37A mediated receptor degradation (12, 29). We 
propose that individual tumor cells can enhance their selective advantage in the 
course of disease progression via down-regulation of hVps37A. This subset of 
tumors could be more sensitive to a disruption of the EGFR pathway by EGFR 
targeted therapy using monoclonal antibodies or small molecule tyrosine kinase 
inhibitors (TKIs). So far, cetuximab has been studied and found ineffective in ovarian 
cancer in several phase II clinical trials (25, 30-32). Cetuximab is known to down-
regulate EGFR signal transduction by various mechanisms, including induction of an 
immune response to the Fc-region in-vivo (33) also known as antibody dependent 
cellular cytotoxicity (ADCC). The role of ADCC in cetuximab mediated anti-tumor 
activity has been studied extensively (34), though the proportion to which ADCC and 
the immune system contribute to the clinical activity of cetuximab is controversial 
(35). In our study we focused on inhibition of EGFR downstream signaling by 
cetuximab, which is abrogated by hVps37A loss and could presumably be a 
determinant of its clinical activity. 
While there are various mechanisms leading to resistance against anti-EGFR- 
therapies, including autocrine EGFR activation, mutation of downstream signaling 
effectors, and cross-activation of alternative RTKs, recently published studies add an 
additional twist: Cancer cell lines resistant to cetuximab by long term exposure 
developed increased EGFR levels as a result of defective receptor degradation (15). 
The genetic knockdown of hVps37A and the resulting resistance to cetuximab in our 
model confirm this molecular mechanism and propose a model of a pre-existing 
cetuximab resistance in advanced ovarian cancer. Further, in addition to the 
antagonistic effects, cetuximab also possesses the potential to trigger EGFR 
activation and dimerization prior to its down-regulation (36, 37). Following incubation 
with cetuximab, MAPK pathway and Akt-pathway remained active in hVps37A-
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deficient cell lines, arguing for sustained functional signaling of the EGFR-cetuximab 
complex, resulting in resistance to cetuximab and unrestrained cell proliferation. In 
contrast to cetuximab, lapatinib directly blocks EGFR activation by targeting the ATP-
binding domain. This leads to defective EGFR-dependent signal transduction 
independently of ESCRT mediated receptor down-regulation (38). This is in line with 
our observations, that PI3K/Akt and MAPK pathways, as well as cell proliferation, 
were inhibited by lapatinib irrespective of hVps37A expression levels. 
Overall, we see hVps37A as a novel tumor suppressor gene with an essential 
role in receptor tyrosine kinase degradation pathway. We propose a clinical 
relevance for measuring hVps37A expression, in order to evaluate it further as a 
potential biomarker in ovarian cancer and beyond. 
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Figure Legends 
Figure 1: Expression of hVps37A, EGFR and HER2 in ovarian cancer. 
(A)Tissue microarrays composed of 125 primary ovarian tumor samples and 19 
borderline tumors spotted in triplicates with corresponding, surrounding normal tissue 
were stained for hVps37A, EGFR, HER2. The stainings were graded on a scale from 
0-3 as 0-no expression, 1-weak expression, 2-moderate expression, 3-strong 
expression. Magnification 40x. 
 
Figure 2: hVps37A status modifies the prognostic potential of EGFR and HER2 
expression. 
(A-G) Survival analysis was performed and depicted in plots of the corresponding 
Kaplan-Meier estimates. (A), (D) and (G) show unstratified Kaplan-Meier survival 
plots based on HER2, EGFR and hVps37A expression of TMA tissues. Samples 
were then stratified according to hVps37A expression and re-analyzed. Only tumors 
with low hVps37A expression retain the prognostic effect of EGFR (F) and HER2 (C) 
overexpression, while in patients with normal (high) hVps37A expression, neither 
EGFR (E) nor HER2 (B) expression influence overall survival. 
 
Figure 3: hVps37A mRNA is decreased in ovarian cancer as compared to 
normal ovaries. hVps37A knockdown is associated with pEGF/pHER2 
accumulation. 
(A) hVps37A mRNA expression in tumor tissue of an independent cohort of 115 
ovarian cancer patients (PT) and 20 age matched normal controls (N). Student’s t-
test was used to compare mean mRNA expression levels of hVps37A. 
(B) hVps37A is silenced upon doxycycline treatment in SK-OV-3tet off cells, while 
hVps37A mRNA expression remains unaffected by doxycycline in SK-OV-3 wild type 
cells.  
(C) Silencing of hVps37A leads to an increase in HER2 and EGFR phosphorylation. 
SK-OV-3tet off cells containing the hVps37A shRNA construct were cultivated in 
presence or absence of doxycycline and analyzed by SDS-PAGE and 
immunoblotting.  
(D) pEGFR (red) accumulates in hVps37A silenced cells and is colocalized with early 
endosomal marker (EEA1, blue). SK-OV-3tet off cells were cultivated in presence or 
absence of doxycycline on chamber slides, probed against pEGFR and EEA1 and 
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analyzed by confocal microscopy. Colocalization of the pEGFR (red) and EEA1 
(blue) signal is indicated by arrows. Green fluorescence of the nuclei arises from the 
presence of an EGFP cassette in the Tet-Off vector. 
 
Figure 4: Loss of hVps37A impairs hVps37A degradation and cetuximab 
sensitivity in ovarian cancer cells. 
(A) Time-pulsed activation of pEGFR is sustained in hVps37A silenced cells. SK-OV-
3tet off cells cultivated in presence or absence of doxycycline were starved by serum 
withdrawal, then pulsed with 100ng/ml EGF and cultivated for indicated time in 
serum-free medium. pEGFR and EGFR levels were determined by SDS-PAGE and 
immunoblotting. 
(B) hVps37A negatively correlates with pEGFR/EGFR ratio. hVps37A, EGFR and 
pEGFR protein amounts were determined in 15 ovarian and breast cancer cell lines 
by immunoblotting. Statistical significance was tested by Pearson Correlation (r=-
0.719) with a p-value of 0.005 
(C) hVps37A silencing leads to resistance against cetuximab mediated EGFR 
inhibition. SK-OV-3tet off cells cultivated in presence or absence of doxycycline were 
incubated for 24 hours with either 20µg/ml cetuximab, or 4µM lapatinib or remained 
untreated. Protein levels of pAkt, Akt, pErk1/2, Erk1/2 and actin were then 
determined by Western blotting.  
(D) hVps37A silenced cells are resistant to cetuximab. 2x105 SK-OV-3tet off cells were 
cultivated in presence or absence of doxycycline and exposed to 20µg/ml cetuximab, 
or 4µM lapatinib or remained untreated (U). Cell number was determined every 48 
hours by a CASY cell counter over 8 days. Doubling time (dt) was calculated, 
normalized to untreated control and depicted as 1/dt. The columns indicate the mean 
of three independent experiments; error bars represent +/-SEM. 
 
Figure 5: hVps37A silencing induces invasive phenotype in-vitro and tumor 
growth in-vivo. 
(A) SK-OV-3tet off cells cultivated in presence or absence of doxycycline were cultured 
in a collagen matrix. Spheroids were analyzed by light microscopy.  
(B) Area of outgrowing cells depicted in percentage relative to central spheroid. Error 
bars indicate mean +/- SEM. 
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(C) Tumors with silenced hVps37A exhibit enhanced growth in-vivo. Mice either 
treated or not-treated with doxycycline orally were inoculated with SK-OV-3tet off 
shRNAhVps37A cells and examined for tumor formation. Mean tumor volume (mm3) in 
treated and untreated mice is depicted against time (days). Error bars represent +/-
SEM. 
(D) In order to control for sustained hVps37A knockdown, formalin fixed-paraffin 
embedded tumor sections were immunostained with the hVps37A specific antibody. 
Magnification 40x. 
(E) Average counts of apoptotic cells per field of view (Magnification 40x, triplicate 
counts) in tumors. Error bars indicate +/- SEM. 
(F) Left panel shows representative Ki-67 stainings in mice xenografts (Magnification 
10x and 40x). Right panel describes the quantitation (percentage) of Ki-67 positive 
cells. Error bars indicate +/- SEM.  
 
Supplementary Figure Legends 
Supplemetary Figure 1: hVps37A protein expression affects specificity and 
sensitivity of HER2 and EGFR testing.  
(A-D) Area under the curve (AUC) shows that the prognostic value (sensitivity versus 
specificity) of EGFR and HER2 testing is dependent on hVps37A expression. Logistic 
regression (ROC curves) was used to calculate specificity and sensitivity for the 5-
year survival prognosis of EGFR and HER2. 
 
Supplemetary Figure 2: Loss of hVps37A impairs hVps37A degradation and 
cetuximab sensitivity in ovarian cancer cell line MDAH-2774. 
(A) hVps37A mRNA is silenced by stable hVps37A specific shRNA expression in 
MDAH-2774 cells, as compared to vector controls 
(B) Silencing of hVps37A leads to an increase in EGFR phosphorylation. MDAH-
2774 cells containing the hVps37A shRNA construct were analyzed by SDS-PAGE 
and immunoblotting.  
 (C) Time-pulsed activation of pEGFR is sustained in hVps37A silenced cells. MDAH-
2774 cells with and without stable hVps37A specific shRNA expression were starved 
by serum withdrawal, then pulsed with 100ng/ml EGF and cultivated for indicated 
time in serum-free medium. pEGFR and EGFR levels were determined by SDS-
PAGE and immunoblotting. 
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(D) hVps37A silencing leads to resistance against cetuximab mediated EGFR 
inhibition. MDAH-2774 cells with and without stable hVps37A specific shRNA 
expression were incubated for 24 hours with either 20µg/ml cetuximab, or 4µM 
lapatinib or remained untreated. Protein levels of pAkt, Akt, pErk1/2, Erk1/2 and actin 
were then determined by Western blotting.  
(D) hVps37A silenced cells are resistant to cetuximab. 2x105 MDAH-2774 cells with 
and without stable hVps37A specific shRNA expression were exposed to 20µg/ml 
cetuximab, or 4µM lapatinib or remained untreated. Cell number was determined 
every 48 hours by a CASY cell counter over 8 days. Doubling time (dt) was 
calculated, normalized to untreated control and depicted as 1/dt. The columns 
indicate the mean of three independent experiments; error bars represent +/-SEM. 
 
Supplemetary Figure 3: Specificity of the monoclonal hVps37A antibody. 
SK-OV-3tet off shRNAhVps37A cells were cultivated in presence or absence of 
doxycycline on chamber slides for 24 hours, fixed with 4% paraformaldehyde for 15 
minutes, and permeabilized with 0.1% Triton X-100. The subsequent staining 
procedure was performed as described for immuno-histochemistry. Primary hVps37A 
antibody was omitted in the “no antibody” controls. 
 
Supplemetary Figure 4: Confirmation of in-vitro and in-vivo effects of hVps37A 
loss. 
(A) Wound healing assay. SK-OV-3tet off shRNAhVps37A cells were plated in 6-well 
plated and cultivated in presence or absence of doxycycline for 12 hours, scratched 
using a sterile pipette tip and cultivated for another 24 hours with or without 
doxycycline. Wound closure was assessed by light microscopy. Accelerated 
migration can be observed in PBS treated SK-OV-3tet off shRNAhVps37A. 
 (B) Tumors with silenced hVps37A exhibit enhanced growth rates in-vivo. Mice 
either treated or not-treated with doxycycline orally were inoculated with SK-OV-3tet off 
shRNAhVps37A cells and examined for tumor formation. Relative tumor growth (x-fold 
volume of the tumor initially measured) is depicted against time (days). error bars 
represent +/-SD.  
 
Supplemetary Figure 5: hVps37A expression in lung cancer. 
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FFPE tissues from two patients with lung cancer were analyzed for hVps37A 
expression by immunohistochemistry. We could observe strong staining in tumor 
tissue as well as stromal expression of hVps37A. Differential expression of hVps37A 
in lung and head and neck cancers is currently being studied by our group 
(unpublished data). 
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Tables 
 
Table 1. Tissue Microarray RNA 
Patients’ characteristics N (percent) N (percent) 
Type   
Normal ovaries  20  
Primary tumors 125  115  
Recurrent tumors   
Borderline tumors 19  
Grade 117 (8 missing)  114 (1 missing) 
1 20 (17.1) 3 (2.6) 
2 26 (22.2) 52 (45.6) 
3 71 (60.7) 59 (51.8) 
FIGO 125 113 (2 missing) 
I 31 (24.8) 19 (16.8) 
II 14 (11.2) 10 (8.9) 
III 72 (57.6) 59 (52.2) 
IV 8 (6.4) 25 (22.1) 
Histology 125 115 
Serous 70 (56.0) 70 (60.9) 
Non-serous 55 (44.0) 45 (39.1) 
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Table 2. hVps37A expression and clinicopathological variables 
 hVps37A 
 high low 
EGFR 
high 39 44 
low 16 45 
HER2 
high 14 25 
low 41 64 
Grade 
1 8 12 
2 11 15 
3 30 41 
FIGO 
I 14 33 
II 7 7 
III 31 44 
IV 3 5 
Histology 
Serous 29 41 
Non-serous 24 31 
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